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Preface 
 
This thesis concludes research carried out mainly at the DTU Food (National 
Food Institute), Technical University of Denmark (DTU) stretching from 2009 until 2012. 
The studies were supervised by Professor Tine Rask Licht, research manager of the 
Intestinal Microbial Ecology group and co-supervised by Doctor Andrea Wilcks, Associated 
Professor Thomas Hjort Skov and Doctor Jørn Smedsgaard, head of Food Chemistry. 
The work presented here is the result of a multidisciplinary project, aiming to study 
metabolic influence of the probiotic and prebiotics on the human health. Collaboration 
between the Division of Food Microbiology, Division of Food Chemistry at DTU, 
Copenhagen University and studies done at the Auckland University made the journey of 
gut ecology metabolomics feasible.  
Project “Bacterial Impact on the Gut Metabolome” was supported by the 
Danish Strategic Research Council’s Committee on Food and Health, FøSu, Center for 
Biological Production of Dietary Fibers and Prebiotics; Øresund Food Network and 
Technical University of Denmark.       
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Summary 
 
The human gastrointestinal tract (GIT) is colonized by a dense and complex community of 
bacteria. This affects the host through modulation of the immune system, protection 
against pathogens, development of the intestinal microvilli, enteric nerve regulation, 
promoting angiogenesis and conversion of nutrients and metabolites. Therefore, human 
global metabolism at the whole-body level is the integration between the activities of our 
genome and the microbiome. As the human GIT provides nutrients to cells and tissues via 
the circulatory system, so do the metabolic products from the microbial flora. In other 
words, every human cell is somehow influenced by metabolites originating from the gut 
microbiota. This cross-talk between the microbes and the host includes signaling via low 
molecular weight metabolites, peptides and proteins. Throughout the decades of studies it 
has become evident that the intestinal microbiota can be modulated by intake of probiotic 
and prebiotic dietary supplements. Recently scientists have addressed the effects of these 
dietary interventions on the presence of specific bacterial metabolites, which are 
anticipated to play a role in gut health.  
In this thesis, by using the metabolomics tools, the impact of the selected well-described 
probiotic bacteria, Lactobacillus acidophilus NCFM, on the simplified intestinal 
metabolome of the germ-free animals was evaluated. The studies attempted to map 
metabolites produced by the NCFM strain when growing in vitro, and in the intestinal 
environment as well as mapping host metabolites induced by the presence of the bacteria. 
In vitro studies with NCFM showed that this strain in the presence of a simple 
carbohydrate source (glucose) increased the concentration of lactic acid, succinic acid, 
adenine and arginine in the medium after 24 h of fermentation, using adenosine and 
glucose as the primary source of energy. Lactic acid and succinic acid, produced by the 
probiotic strain could have a beneficial effect on the host, lowering the pH in the intestines 
and thereby protecting from pathogenic infections and cancer development. However, the 
GIT is a much more complex environment that is affected by the nutrition available for the 
bacterial fermentation and mammalian metabolites interacting with the probiotic. 
Therefore, a simplified mammalian model, the germ-free mice studies, was established to 
analyze the influence of NCFM on the host. Our initial analyses, comparing germ-free and 
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monocolonized animals with NCFM, showed a distinctive differences in the metabolism 
throughout the mammalian GIT as well as global metabolism, represented by plasma and 
liver samples.  
To increase the knowledge about bacterial metabolites created by prebiotic fermentation, 
and the impact of the size (chain length) of the sugar beet arabino-oligosaccharides 
(AOS), in vitro fermentations with human fecal microbial communities were used. The 
metabolic and phylogenetic response to high-mass AOS was found to be the most similar 
to commercially available prebiotic fructo-oligosaccharides. High-mass AOS in comparison 
to the low-mass and base fraction (mixture of the two fractions) caused the highest 
increase of metabolites putatively beneficial to the human gastrointestinal tract.   
Probiotic and prebiotic influence on the host looks for the beneficial aspect of the bacterial 
flora. However the GIT is not only inhabited by beneficial microbiota, but also potential 
pathogens. A balanced microflora requires that the bacterial composition work in a co-
metabolic symbiotic relationship with the host, supporting the complex system. An 
unbalanced composition might potentially be the beginning of many diseases, such as 
inflammatory bowel diseases and, in particular, Ulcerative Colitis (UC). Our metabolomic 
studies have shown significant differences in the metabolism between microflora from UC 
patients in relapse and remission or healthy individuals. The metabolomic-angled look on 
UC microflora constitutes an important contribution to the understanding of the complex 
etiology behind UC.   
In conclusion, studies of the GIT bacterial activity revealed a potentially significant impact 
of the gut microflora and on the host metabolome in relation to the dietary modulation and 
in the diseased state of UC. 
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Dansk sammendrag 
 
Den menneskelige mave-tarmkanal er koloniseret af en tæt og meget kompleks gruppe af 
bakterier. Dette påvirker værten gennem modulation af immunforsvaret, beskyttelse mod 
patogener, udvikling af mikrovilli i tarmen, regulering af enteriske nerver, fremning af 
blodkardannelse og omdannelse af næringsstoffer og metabolitter.  Det globale 
menneskelige stofskifte for hele kroppen er derfor integrationen mellem aktiviteterne i 
vores genom og aktiviteterne i det mikrobiologiske biom. På samme måde som 
menneskets mave-tarmkanal leverer næringsstoffer til celler og væv via blodomløbet, 
ligeledes leveres metabolitter fra den mikrobiologiske flora. Med andre ord, hver eneste 
menneskelige celle er påvirket af metabolitter der stammer fra de mikrobiolgiske 
økosystem i mave-tarm systemet. Denne tværgående kommunikation mellem mikrober og 
værten inkluderer signalering via lav-molekylærvægt metabolitter, peptider og proteiner. 
Gennem flere årtiers studier er det blevet tydeligt at de mikrobiolgiske bakteriefamilier kan 
moduleres ved indtagelse af pro- og prebiotiske kosttilskud. I senere tid har forskere 
undersøgt hvilke effekter denne kost-forårsagede indgriben har på tilstedeværelsen af 
specifikke bakterielle metabolitter, som er forventet at spille en rolle i mave-tarm systemets 
helbred. 
I denne afhandling blev indvirkningen af den udvalgte, velkendte probiotiske bakterie 
Lactobacillus acidophilus NCFM på det forsimplede mave-tarm metabolom i kimfri dyr 
evalueret, ved hjælp af metabolomics teknikker. Studierne forsøgte at kortlægge 
metabolliter der blev produceret af NCFM stammen, når den voksede  henholdsvis in vitro 
og i mave-tarm miljøet og ydermere  at kortlægge værts metabolitter induceret af 
bakteriens tilstædeverelse. In vitro studier med NCFM viste at denne stamme, efter 24 
timers fermentering, øgede koncentrationen af mælkesyre, ravsyre, adenin og arginin i 
mediet i tilstædeværelsen af en simpel kulhydratkilde (glukose). Glukose og adenosin var 
de primære energikilder. Mælke- og ravsyren produceret af den probiotiske stamme kunne 
havde en gavnlig effekt på værten ved at sænke pH-værdien i mave-tarm systemet og 
derved beskytte mod patogen infektioner og udvikling af kræft. Den menneskelige mave-
tarmkanal er dog et mere kompleks miljø der bliver påvirket af næringen brugt i bakteriel 
fermentering og mammale metabolitter der interagerer med probioten. Derfor blev en 
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forsimplet mammal model, studier i kimfri mus, etableret for at analyserer hvilken 
indflydelse NCFM har på værten. Vores indledende analyser, der sammenligner kimfri dyr 
med dyr enkeltkoloniserede af NCFM, viste en tydelig forskel i metabolismen i den 
mammale mave-tarmkanal såvel som i den globale metabolisme. Dette blev påvist ved 
hjælp af prøver af blodplasma og lever. 
For at øge viden om bakterielle metabolitter skabt ved prebiotisk fermentering og 
indflydelsen af størrelse (kædelængden) af arabino-oligosakkarider (AOS) fra sukkerroer, 
blev in vitro fermentering med mikrobiologiske kulturer fra  menneske fækalier. Det 
metaboliske og fylogenetiske respons på høj-masse AOS blev bedømt til at være den 
samme respons som set med kommercielle prebiotiske frukto-oligosakkarider. Høj-masse 
AOS gav i forhold til lav-masse og basis fraktioner (en blanding af de to fraktioner) den 
højeste stigning af metabolitter, der er formodet gavnlige for den menneskelige mave-
tarmkanal. 
Pro- og prebiotisk indflydelse på værten ser på det gavnlige aspekt af den bakterielle flora. 
Men mave-tarmkanalen er ikke kun beboet af gavnlige mikrober, den indeholder også 
potentielle patogener. En balanceret mikrobiologisk flora kræver, at den bakterielle 
sammensætning arbejder sammen i symbiotisk metabolisk samarbejde med værten, der 
støtter det komplekse system. En ubalanceret sammensætning kan potentielt være 
begyndelsen af mange forskellige sygdomme, som f.eks. inflammatorisk mave-tarm 
sygdomme og, især,  Ulcerativ Colitis (UC). Vores metabolomiske undersøgelser har vist 
tydelige forskelle i metabolismen mellem den mikrobiologiske flora i UC patienter, der er 
har henholdsvis tilbagefald,  aftagene symptomer og i raske individer. Den metabolomics-
baserede indgangsvinkel på UC mikrobiologisk flora udgør en vigtig tilføjelse til forståelsen 
af den komplekse etiologi bag UC. 
For at konkludere, undersøgelser af den mave-tarmkanal bakterielle aktivitet afslørede en 
potentiel tydelig effekt på mave-tarm systemets mikrobiologiske flora og værtens 
metabolom, i forhold til diætmodulation og sygdomstilstanden fra UC. 
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Objectives of the study 
 
During the last decade, it has become evident that the complex ecosystem of microbes 
inhabiting the human gut plays an important role for human health [1-3]. Additionally, it has 
become evident that the intestinal microbiota can be modulated by intake of probiotic and 
prebiotic dietary supplements [4,5]. A large number of studies have addressed the effects 
of dietary interventions on the presence of specific bacterial metabolites, which are 
anticipated to play a role for gut health [6]. Recently developed approaches allow 
simultaneous mapping of multiple metabolites present in the gut metabolome [6-13].  
By using the metabolomics tools, the impact of selected well-described probiotic bacteria, 
Lactobacillus acidophilus NCFM, on the simplified intestinal metabolome of the germ-free 
animals was evaluated. This project attempted to map metabolites produced by the NCFM 
strain when growing in vitro, and in the intestinal environment as well as host metabolites 
induced by the presence of the bacteria (Manuscript I and II). 
Non-digestible carbohydrates are mainly known for the influence on the short chain fatty 
acids production. To increase the knowledge about bacterial metabolites created by 
prebiotic fermentation, and the impact of the size (chain length) of the sugar beet arabino-
oligosaccharides, in vitro fermentations with human fecal microbial communities were used 
(Manuscript III).  
Additionally, in search for the etiology of the Ulcerative Colitis, metabolome differences 
between fecal microbial communities of patients and healthy subjects were studied. 
Bacterial influence on the gut was taken into consideration as one of the source of the 
disease (Manuscript IV).  
As bacterial impact on the gut is still a big puzzle, the project aimed at examining the 
metabolic mechanisms between host and microbiota in order to make this puzzle more 
solvable. 
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1. Metabolomics 
 
1.1. Metabolomics concept 
Metabolites are classified as low-molecular-weight compounds, which are related to cell 
metabolism, mostly described as chemicals below 1 kDa [6]. As intermediates of 
biochemical reactions, metabolites have a very important role in connecting many different 
pathways [14] in and across organisms. The complete set of metabolites associated with 
an organism is referred to as a metabolome, which is divided into endo- and exo-
metabolomes, covering intra- and extra-cellular metabolites, respectively. Metabolomics is 
a research field which aims at comprehensive analysis of a metabolome. An unspecific 
analysis of intracellular metabolites is called metabolic fingerprinting. Metabolomics 
focused on the untargeted extracellular part of the metabolome is designated as 
metabolic footprinting [15].  
 
 
Figure 1.1 A flow chart of a metabolomic study. As an example the metabolic profiling of 
urine samples is shown. Figure modified from Chan et. al, 2011 [16].   
Sampling 
Storage Sample 
preparation 
Chemical 
analysis 
Data 
analysis 
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Metabolomics involves sampling, sample preparation, chemical analysis and data 
analysis. A flow chart of a “standard” metabolomic study is shown in Figure 1.1. 
1.2. Metabolic footprinting 
In order to analyze the bacterial impact on the gut metabolome this thesis is focused on 
metabolic footprinting, a set of non-targeted biochemistry studies and data mining of 
extracellular metabolites [17] obtained from the in vitro growth cultures or body fluids (milk, 
plasma, urine). Despite the fact that footprinting represents only a small fraction of the 
whole metabolome, it provides a key understanding of cell and organism communication 
mechanisms, which play a crucial role in the symbiotic relationships between 
gastrointestinal tract (GIT) microflora and the host. In an extracellular environment any 
changes in the abundance and level of extracellular metabolites will directly reflect any 
modifications of the environment caused by activities of microorganism present in the 
system. The connection between the microbial activity (intracellular metabolome) and 
excreted metabolites is presented in Figure 1.2 [18].  
The microbial metabolism is directly influenced by the external environment. Metabolites 
released into the environment are a consequence of cell metabolic activity, modifying the 
external environment. Therefore analysis of the metabolic footprint provides an insight into 
possible microbial metabolic activities that accrues in relation to the presence of natural 
products and potential xenobiotics.     
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Figure 1.2 Coupling between the environment and cell metabolism. Metabolites shown in 
the figure serve as examples. Figure from Mapelli et. al, 2008 [18].   
 
1.3. Metabolomic tools 
As previously mentioned metabolomics aims at the comprehensive analysis of a 
metabolome. Choosing a suitable analytical strategy require several considerations:  the 
information needed, the chemistry expected and the analytical facilities available. The 
nature of the metabolome, intracellular and extracellular, is very complex and no single 
methodology can detect the complete metabolome in one procedure. Key parameters for 
this choice are given in Table 1.1. 
1.3.1. Sampling and sample preparation 
The first and most crucial steps in metabolomic studies are sampling and sample 
preparation. The methodology of sampling and sample preparation for fingerprinting of 
metabolites is dependent on the type of sample (bacterial, yeast cells, animal or plant  
Theoretical part 
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Table 1.1    Key parameters to take into consideration when choosing analytical methods. 
Table adapted from Villas-Boas et. al, 2007 [6]. 
Physicochemical properties of 
metabolites 
Molecular weight and size 
Polarity (polar, non-polar) 
pKa (acidic, alkaline, neutral) 
Concentration (sensibility of detectors) 
Detectability (chromophors, ionizability, etc.) 
Volatility 
Concentration Trace or massive amount 
Matrix 
Interference from co-extracted substrate or from major 
components in the sample 
 
tissue). Comprehensive information, about the choice of methods for metabolism 
quenching and intracellular metabolite extraction is presented by Villas-Boas et al. [19]. 
General steps involved in sample preparation of extracellular metabolites are presented in 
Figure 1.3.  
Cellular metabolism is a dynamic process with very different turnover speeds, depending 
on the concentration of enzymes, substrate availability etc. Analysis of the extracellular 
metabolites requires a fast separation from the cells, which is usually achieved by cold 
centrifugation (1-4°C). Low temperature during centrifugation is necessary to slow down 
the cellular metabolism. Extracellular metabolite turnover, compared to intracellular 
metabolite, is much slower, due to the higher dilution of metabolites. However due to 
several issues, including the presence of cell lyses, release of the intracellular matrix, 
changes in the substrate concentration, activity of extracellular enzymes, chemical 
degradation and chemical interactions, metabolic footprinting still requires a rapid 
inactivation of the metabolism; the metabolism quenching. Inactivation of chemical and 
enzymatic activities is usually done by placing the biological sample in contact with cold (< 
-40°C) or hot (> 80°C) organic solutions or by dramatically changing the pH, typically by 
addition of perchloric acid. Use of liquid nitrogen is also possible, but not very common. 
Storage below -20°C before the analysis prevents further degradation of the samples.    
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Figure 1.3 Sampling and sample preparation of extracellular metabolites. Figure modified 
from Villas-Boas et. al, 2007 [6].  
 
1.3.2. Chemical analysis 
A wide range of analytical tools are used in metabolomics. Some of the more common 
methods are: vibrational spectroscopy, nuclear magnetic resonance (NMR) spectroscopy 
and mass spectrometry (MS).       
Vibrational spectroscopy 
Fourier transform-infrared (FT-IR) is a method used to measure the overall composition of 
a sample by detecting the molecular vibrations and other motions of chemical bonds [20]. 
It has the benefit of enabling rapid, reagentless, non-destructive analysis of very complex 
biological samples. The drawback of this method is its low sensitivity, making the results 
difficult to integrate with biological information [18].    
Nuclear magnetic resonance (NMR) 
Continuous improvements in resolution and sensitivity over the years, has made NMR one 
of the most used techniques in metabolomics [21-25]. The main benefit of NMR is that it is 
specific and nonselective, which means that each resonance observed is specific to a 
particular compound and provides structural information regarding the components of a 
sample. It does not need a pre-selection of analysis conditions, like MS systems [18]. 
Cell suspension 
(in vitro microbial 
growth, blood) 
 
Separation of 
biomass from the 
liquid medium 
(cold 
centrifugation, 
rapid filtration) 
 
Biomass 
Extracellular 
medium 
 
Storage   
(freezing <-20; 
darkness, freeze-
drying) 
 
Denaturation of 
enzymes   
(adding organic 
solvents, freeze-
drying) 
 
Storage   
(freezing <-20°C; 
darkness, freeze-
drying) 
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Additional aspect of NMR is its non-invasive nature, which allows in vivo metabolome 
profiling [26].  
Mass spectrometry (MS) 
Many different and complementary mass spectrometry platforms are employed in 
metabolomic studies. The most recent and common platforms are: direct infusion mass 
spectrometry (DI-MS), gas chromatography, liquid chromatography and capillary 
electrophoresis coupled with MS (GC-MS, LC-MS and CE-MS, respectively).  
With using the DIMS platform metabolites are injected directly in front of the ion source, 
bypassing any separation methods like LC or GC. For this type of analysis time of flight 
(TOF) mass spectrometers are the preferred instruments, providing additional separation 
of ions, depending on their molecular mass. Additionally for all types of MS, TOF 
spectrometers can provide full mass scan abilities and complete mass spectra with good 
sensitivity [27]. DI-MS also allows high-throughput analyses of biological samples. The 
major problem with DI-MS technology is the “matrix effect” [28] and even with the use of a 
TOF spectrometer, DI-MS does not provide a good enough separation of metabolites. The 
mentioned effect can also compromise sensitivity and accuracy of mass analysis [29]. Ion 
suppression, caused by coeluting compounds and isobaric interferences, are also a major 
disadvantage of DI-MS.  
CE-MS, GC-MS and LC-MS give a good separation of metabolites, reducing problem 
related to the direct infusion and also provide the possibility for separation of isomers. A 
good analytical separation will also result in better detection limits and improve MS data 
quality [29].  
CE-MS is a high-resolution technique. However for each type of metabolites (anionic, 
cationic, nucleotides, etc.) a separate methodology needs to be set up to achieve a 
comprehensive coverage of metabolome, which prolongs the analysis time per sample 
[30].  
The most commonly used metabolomic techniques are GC-MS and LC-MS. The 
combination of gas chromatography with electron impact MS provides high 
chromatographic metabolite resolution, analyte-specific detection, quantification of 
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metabolites and the possibility to indentify unknown metabolites [31]. However, a major 
disadvantage of GC-MS is that analysis of polar metabolites usually requires 
derivatisation, increasing their thermal stability and volatility, which complicates the sample 
preparation process. The choice of reagents must be based on the stability of the 
derivatives and a low amount of by-products from the derivatisation process. Moreover, 
artifacts can be formed during derivatisation [32], complicating data interpretation. A big 
advantage of the GC-MS system is the presence of many metabolic databases, making 
the identification of componds much easier compared to the LC-MS [33].  
Liquid chromatography gives a good separation of metabolites. Depending on the type of 
LC a wide range of metabolites can be covered by this method through the ionization in 
positive and negative mode with very good sensitivity. LC-MS does not require 
derivatisation, making the sample preparation easier to perform relative to GC-MS. LC-MS 
enables the possible analysis of thermo-labile metabolites. A few drawbacks of this system 
are possible matrix effects, sometimes requirement on desalting the samples, limited 
structural information and identification [34,35]. Identification difficulties could be overcome 
by the use of MS-MS techniques [36].                     
1.3.3. Data analysis 
Chemical analysis of the metabolome results in a large number of data points per sample, 
placing the data in a multidimensional space. Ideally all measured metabolites should be 
identified. However, among the great number of variables often only a few are of interest, 
these few providing necessary biological information. The data processing in 
metabolomics aims at finding and identifying those few important variables. A flow chart of 
the metabolomic data analysis is shown in Figure 1.4.  
First the acquired data is converted into a matrix as used by most of the multivariate 
analysis. Preprocessing of data requires signal to noise improvement and data 
normalization. Multivariate data analysis allows evaluation of the data quality, based on the 
replicates of samples and detection of outliers. More importantly, this greatly reduces the 
amount of metabolic candidates for further identification. A summary of the main 
multivariate methods and their use is given in Table 1.2 [37]. 
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Figure 1.4 Data analysis flow chart in relation to the metabolomic studies (S/N signal to 
noise ratio) [6,17,19].       
      
Extensive information about the methods in Table 2 can be found in Lattin et al.. In 
metabolomics the most popular methods reducing the dimension are Component Analysis 
(CA) and Discriminant Analysis (DA), often used as complimentary methods [24,38-40]; 
CA as an independent (unsupervised) method and DA as a dependent (supervised) 
method.  
Principal Component Analysis (PCA) uses an orthogonal transformation to convert a set of 
observations, possibly correlated variables into a set of values, linearly uncorrelated 
variables called principal components (PC). This transformation is defined in such a way 
that the first principal component has the largest possible variance, which means that it 
accounts for as much of the variability in the data as possible. Each succeeding 
component in turn has the highest variance possible under the constraint that it be 
orthogonal to (uncorrelated with) the preceding components.  
This way the PCs describing the highest number of variations can be selected to represent 
the data in a lower dimensional space. PCA results in the decomposition of raw data into 
“scores”, which reveal the relationship between samples and into “loadings” that show the 
relationships between the variables (Figure 1.5).  
 
 
 
Acquisition Pre-processing 
Data 
reduction 
Data 
analysis 
Chromatogram 
Mass spectra 
Storage 
S/N improvement 
Normalization 
Deconvolution 
Univariance analysis 
Multivariate data 
analysis  
Outliers exclusion  
Data quality check 
Metabolite 
identification 
Biological information 
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Table 1.2    Examples of multivariate methods. Table adapted from Lattin et. al, 2003 [37]. 
Method Type of Analysis Objectives 
Principal Components I, E Dimension reduction 
Factor Analysis I, E or C 
E - Understand patterns of intercorrelation; 
uncover latent traits and C – verify 
measurements models 
Multidimentional Scaling I, mainly E Create spatial representation from object similarities 
Cluster Analysis I, E Create groupings from object similarities 
Canonical Correlation D, mainly E Explain covariation between two sets of multiple variables 
Structural Equation Models 
with Latent Variables D, C Dependence model with measurement error 
Analysis of Variance D, C Special case of canonical correlation with discrete X variables 
Discriminant Analysis D, E or C Special case of canonical correlation with discrete Y variables 
Logit Choice Models D, E or C Nonlinear probability model for discrete choice outcomes 
I, D, E and C designated as Independent; Dependent; Exploratory and Confirmatory analysis 
respectively  
 
For the PCA method to be successful in pattern visualization it should capture the group 
segregation. However, PCA can be affected by noise in the variables (e.g. matrix in 
chromatogram analysis), which could distort the analysis. PCA, maximizing the variation, 
does not consider group information. Discriminant analysis, such as Fisher (linear) 
Discirminant Analysis (FDA) and Partial Least Squares Disciriminant Analysis (PLS-DA), 
maximizes between-groups variation, while minimizing the within-group variation. FDA and  
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Figure 1.5 Example of PCA plots; (A) PCA scores plot based on 1H NMR spectra of urine 
samples from rats; (B) PCA loading plot corresponding to the score plot. Figure from 
Ronghui et. al, 2008 [41]. 
 
PLS-DA are supervised methods that use given grouping information for the data 
projection, which captures the group information and neglects the noise. Supervised 
methods have the tendency to overfit the data [37]. Therefore, cross-validation (technique 
for assessing how the results of a statistical analysis generalize to an independent data 
set) of the models is always necessary. There are many factors that may impact the result 
of statistical analysis of metabolomic data, such as choice of supervised and unsupervised 
methods, the normalization and scaling techniques. It is therefore wise to investigate 
several different options. 
The last step in the metabolic studies (Figure 1.4) is the metabolite identification and 
correlation with the biological information. LCMS and GCMS systems often provide peak 
detection, identification and integration. Most software includes additional analytical tools, 
which are able to use either self-created or commercial mass spectra libraries for 
compound identification. However, GCMS provides more stable retention times between 
the systems, allowing system to system comparisons and presence of many commercially 
available databases [33]. Based on the exact mass to charge (m/z) ratio and MSMS 
analysis, LCMS online data bases [42,43] provide appropriate information allowing 
metabolite identification. Biological interpretation of the data is often based on the 
metabolic pathway correlations [14] publically available and standard literature studies, 
which connects the pieces of the metabolomic puzzle.  
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2. Human gastrointestinal tract 
 
2.1. Human digestive system 
The human GIT is divided into the oral cavity, esophagus, stomach (upper digestive tract), 
small intestine, colon, rectum and anus (large intestine). The small intestine is composed 
of the duodenum, jejunum and ileum. The GIT together with the associated organs, 
salivary glands, liver, gallbladder and pancreas constitute the digestive system (Figure 
2.1). The digestive system is responsible for the breakdown and modification of food into 
smaller portions and usable nutrients, electrolytes, and fluids. In addition, it excretes 
unabsorbed residues, provides a protective barrier against the entry of toxic substances 
and infectious agents, serves as the largest endocrine organ in the body and interacts with 
other endocrine organs: the nervous system, circulatory system, immune system, and so 
on [44]. The digestion and absorption of nutrients depends on the softening, mixing and 
movement of the content along the GIT.  
In the oral cavity, foods are masticated and lubricated with saliva. This process initiates the 
breakdown of food in a manner that will allow penetration and action of digestive enzymes. 
The secretion from the salivary glands contains enzymes; primarily α-amylase. The 
stomach is a capacious organ that mixes ingested food with gastric secretions to facilitate 
digestion. It is interposed between the esophagus and the small intestine. Digestive 
enzymes from pancreas and bile acids from the gallbladder mix in the duodenum. The 
digestive enzymes break down proteins and bile emulsify fats into micelles. The 
duodenum contains Brunner’s glands that produce bicarbonate, which in combination with 
bicarbonate from pancreatic juice neutralizes stomach acids from the stomach. The 
jejunum, connecting the duodenum and the ileum as well as the colon, is able to absorb 
nutrients into the bloodstream due to a large surface area. Nutrients include 
monosaccharides, amino acids and fatty acids and water [45]. The time it takes a 
substance to travel through the entire GIT is on average between 24 and 72 hours, of 
which most (18-64 hours) is spent in the colon. Transit time through the stomach and small 
intestine is only about 4 to 8 hours [46].  
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Figure 2.1 Schematic representation of the human digestive system [47]. 
 
2.2. Microbiota in the gastrointestinal tract 
The human GIT is colonized by archaea, eukarya and a dense and complex community of 
bacteria all of which have a large impact on the health of the host. The host is affected 
through modulation of the immune system, protection against pathogens, development of 
the intestinal microvilli, enteric nerve regulation, promoting angiogenesis and conversion of 
nutrients and metabolites [48]. Proportionally, the human body consists of only 10% 
human cells and the remaining 90% are cells of microbial origin. Thus, there is more than 
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one genome within the human body, the human genome and the microbial, creating the 
symbiotic organism recently described as “superorganism” [49]. The total number of 
microorganisms in the GIT is around 1014 and varies greatly between different regions of 
the gut [50]. Despite the importance of the GIT microflora, little is known with respect to the 
microbial composition, species diversity and their metabolic activity. However, recently 
developed culture-independent studies [51] and metabolomics applied to the GIT bacteria 
[10,22,52] have helped to increase the knowledge greatly.  
The intestinal microbiota differ quantitatively and qualitatively, increasing in number and 
population diversity along the length of the GIT (Table 2.1). The oral cavity is colonized by 
a wide array of aerobic, facultative and anaerobic organisms. Whereas the oxidation-
reduction potential decreases, more anaerobic bacteria colonize the distal part of the GIT; 
thus, over 99% of bacteria located in the large intestine are anaerobes [53,54]. After the 
approximately neutral pH of the oral cavity, the low pH of the stomach (2.5 – 3.5) is 
destructive to most microbes. Low number of bacteria (103 CFU/g, Table 2.1) is dominated 
by Gram-positive bacteria [55]. The proximal part of the small intestine with low pH, bile 
and pancreatic secretions and a low transit time is still a hostile environment for most 
microbes. A pH gradient to the distal part of the small intestine allows a higher number 
(105 – 108 CFU/g [55]) and more diverse bacteria to colonize. Studies showed that jejunum 
microbiota is dominated by Streptococus and Proteobacteria, and the distal ileum by 
Bacterioidetes and Clostridium [56].  
In humans, the colon is the most predominant site for fermentation (Figure 2.2). Due to the 
slower transit, rich nutritional environment and high pH the bacterial density and diversity 
is much higher (109 – 5x1011 CFU/g; Table 2.1). The proximal colon is a saccharolytic 
environment where most bacterial metabolic activity and non-digestible carbohydrate 
fermentation occur. The pH of the proximal colon is generally lower than the distal part (5-
6 and neutral respectively). The reduced pH is considered to be an outcome of 
carbohydrates fermentation, resulting in the production of Short-Chain Fatty Acids (SCFA) 
[57]. In the distal colon, availability of carbohydrates decreases and the pH increases. 
Bacterial metabolism is slower and proteolysis is the dominating process. Despite the 
vertical difference in the bacterial population, there is also a horizontal stratification, with 
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different microbial communities inhabitating the intestinal lumen, mucus, crypt spaces and 
directly adhering to epithelial cells [58].   
Table 2.1    Estimated numbers of major microbial population groups in different segments 
of the GIT. Table from Holzapfel, 2006 [59]. 
Microbial group 
Stomach Duodenum Jejunum & Ileum Colon 
101 – 103 
CFU/ml 10
1 – 104 CFU/ml 105 – 108 CFU/g 10
9 – 5x1011 
CFU/g 
Actinomyces spp.   104 – 106  
Bacteroides-Prevotella-
Porphyromonas group up to 10
2 ca. 103 104 – 107 109 – 1011 
Bifidobacterium spp.    109 – 1010 
Clostridium spp.   104 – 105 108 – 109 
Coprococcus cutactus    107 – 108 
Enterobacteriaceae up to 102 102 – 104 103 – 106 105 – 107 
Enterococcus spp.   102 – 104 103 – 106 
Eubacterium spp.    109 – 1011 
Fusobacterium spp.   103 – 105 105 – 107 
Lactobacillus spp. 101 – 103 102 – 104 104 – 106 105 – 108 
Megamonas 
hypermegas    10
7 – 108 
Megasphaaera elsdenii    107 – 108 
Methanobacteria    up to 104 
Peptostreptococcus 
spp.   10
2 – 106 108 – 109 
Proteus spp.    103 – 106 
Pseudomonas spp.    > 103 
Staphylococcil    ca. 103 
Streptococcus spp. 101 – 103  103 – 108 up to 107 
Veillonella spp.   103 – 107 105 – 108 
Yeasts    ca. 103 
 
Most studies exploring the human intestinal microbiota are focused on the fecal microflora 
due to its easy access and collection. However, it has been postulated that the fecal 
microbial populations may be distinct and have different properties than the surface-
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adherent microbes in the colon mucus [60]. It has to be taken into consideration that the 
fecal bacterial population is not a representation of the total GIT microflora.  
 
Figure 2.2 Fermentation in the colon. Figure from Guarner and Malagelada, 2003 [61].  
 
2.3. Metabolic relationship between the host and microflora 
Human global metabolism at the whole-body level is the integration between the activities 
of our genome and the microbiome. As the human GIT provides nutrients to cells and 
tissue by the circulatory system, so do the metabolic products from microbial flora. In other 
words, every human cell is somehow influenced by metabolites originating from the gut 
microbiota [62]. This cross-talk between the microbes and the host includes signaling via 
low molecular weight metabolites, peptides and proteins.  
The most studied metabolic contribution of the intestinal microflora to the GIT of the host is 
the production of the SCFAs. Complex non-digestible carbohydrates from plant sources 
are fermented by the gut bacteria, producing mainly acetate, propionate and butyrate. Host 
recovery of the SCFAs occurs by passive diffusion and mono-carboxylic acid transporters 
[63]. Increases in SCFA production have been associated with decreased pH, which may 
reduce potential pathogenic clostridia, decrease solubility of bile acids, increase absorption 
of minerals, and reduce ammonia absorption by the protonic dissociation of ammonia and 
Theoretical part 
18 
 
other amines [64-66]. Butyrate is the preferred source of energy for colonic epithelial cells. 
Absorbed acetate and propionate are delivered to hepatocytes, consuming propionate for 
gluconeogenesis, and acetate might be used for lipogenesis in colonocytes, hepatocytes 
and adipocytes [67]. SCFA also act as signaling molecules. Propionate, acetate and in a 
small extent butyrate and pentanoate could stimulate expression of leptin, a hormone with 
a pleiotropic effects on appetite and energy metabolism [68].  Acetate is the principal 
SCFA in the colon, increasing cholesterol synthesis. However, propionate, a 
gluconeogenerator, has been shown to inhibit cholesterol synthesis. Therefore, substrates 
that can decrease the acetate:propionate ratio, may reduce serum lipids and possibly 
cardiovascular disease risk [69]. Butyrate has been studied for its role in nourishing the 
colonic mucosa and in the prevention of cancer of the colon, by promoting cell 
differentiation, cell-cycle arrest and apoptosis of transformed colonocytes; inhibiting the 
enzyme histone deacetylase and decreasing the transformation of primary to secondary 
bile acids as a result of colonic acidification [70]. Therefore, a greater increase in SCFA 
production and potentially a greater delivery of SCFA, specifically butyrate, to the distal 
colon may result in a protective effect [69,71]. The production of SCFAs is dependent on 
the number and types microflora in the colon, type of substrate and the gut transit time 
[66,72]. Mostly related bacterial taxa, associated with the SCFAs production are Clostridial 
clusters IV and XIVa, Eubacterium, Roseburia, Faecalibacterium and Coprococcus 
[65,67,69].  
Colonic bacteria also contribute to the salvage of bile salts, which escape active transport 
in the distal ileum. The two primary bile acids synthesized in the human liver are cholic 
acid and chenodeoxycholic acid, conjugated to the bile salts. Ileal bile salt transport is 
highly efficient (95%), but a small fraction escapes the enterohepatic circulation and 
becomes substrate for significant microbial biotransformation in the large bowel [73]. The 
major bile salt modifications in the human large intestine include deconjugation, oxidation 
of hydroxyl group and dehydroxylation [74]. Deconjugation and dehydroxylation of bile 
salts increases their hydrophobicity and their Pka, permitting their recovery by passive 
absorption across the colonic epithelium. However, the increased hydrophobicity of the 
transformed bile salts is also associated with increased toxic and metabolic effects. High 
concentrations of secondary bile acids in feces, blood, and bile have been linked to the 
pathogenesis of cholesterol gallstone disease and colon cancer [75]. The main secondary 
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bile acids formed by the interaction of both human and intestinal microbial metabolism are 
deoxycholic acid and lithocholic acid. Figure 2.3 shows bacterial bile salt-biotransforming 
reactions present in the human GIT. Studies done with the HBM (human baby flora) 
colonized mice showed that significant variations in microbial populations lead to 
modification of bile acid symbiotic metabolism [76]. The deconjugation of bile acids 
involves the activity of bile salt hydrolase, which is synthesized in significant amounts by  
  
 
Figure 2.3 Bacterial bile salt-biotransforming reactions in the human intestinal tract. 
Hydroxy group carbons of cholate are numbered and the AB rings are identified. The 3, 7, 
and 12 carbons of cholic acid are numbered. BSH, bile salt hydrolase; HSDH, 
hydroxysteroid dehydrogenase. Figure from Ridlon, 2006 [74].  
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Lactobacillus and Bifidobacterium [77]. Another study showed that biotransformation of the 
bile salts was highly influenced by the balance between Lactobacillus and Bifidobacterium 
and Enterobacteria and Bacteroides [78]. Other bacterial genus related to the bile acid co-
metabolism are Clostridium and Escherichia [73,74,79,80].  
Bile acids are amphiphilic compounds, and their biotransformation modifies their 
hydrophobic/hydrophilic balance, which directly relates to lipid emulsification and 
eventually absorption [81-83]. Recent findings show the essential microbial role in affecting 
the bile acid-controlled signaling pathways, involved in energy and lipid metabolism [84]. 
For instance, cholesterol-lowering effects and protection against very-low-density 
lipoproteins (VLDLs) and low-density lipoproteins (LDLs) oxidation were reported for 
Lactobacillus and Bifidobacteria [85,86]. Other studies indicate microbiota in the GIT can 
modulate the host’s lipid storage and metabolism [87-89]. The symbiotic metabolism 
between the mammalian host and the bacterial microflora related to the bile acids and lipid 
metabolism is presented in Figure 2.4.  
Liver metabolism is influenced by the microbial biotransformation of choline, which is an 
essential dietary nutrient. However, intestinal microbiota also convert dietary choline to 
trimethylamine, which is then further metabolized in the liver to trimethylamine-N-oxide 
[90]. The final metabolite is known for its negative impact on the cardiovascular system, 
involvement in the atherosclerosis and nonalcoholic fatty liver disease [22]. Bacteria 
related to the transformation of choline are Faecalibacterium prausnitzii and 
Bifidobacterium [71,91].  
Flavonoids are polyphenolic compounds that occur ubiquitously in foods of plant orgin. 
Variations in the heterocyclic ring divide them into flavonols, flavones, catechins, 
flavanones, anthocyanidins and isoflavonoids. A multitude of in vitro studies have shown 
that flavonoids can inhibit or induce a large variety of mammalian enzyme systems, 
involved in important pathways, regulating cell division and proliferation, platelet 
aggregation, detoxification, and inflammatory and immune response [92]. It has been 
hypothesized that the antioxidant properties of flavonoids may protect tissues against 
oxygen free radicals and lipid peroxidation, which might be involved in several pathological 
conditions [93,94]. Absorption of flavonoids from the diet was long considered to be 
negligible, as they are present in foods bound to sugars as β-glycosides, except catechins.  
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Figure 2.4 Microbe-mammalian metabolic interactions related to bile acid and lipid 
metabolism. The bacterial reprocessing of the bile acid pool and regulation of bile acids 
metabolism by bacterial SCFAs significantly affect the enterohepatic recirculation and the 
systemic lipid metabolism, which are emulsification, absorption and transport of dietary 
fats. The gut-bacterial-induced regulation of enterohepatic recirculation also leads to a 
physiological regulation of oxidative stress (glutathione), reprocessing of fatty acids 
(deposition, apoprotein and VLDL synthesis) and VLDL secretion from the liver, which 
results in controlling of the influx and efflux of fatty acids in the liver. BA, bile acids; CA, 
cholic acid; GPC, glycerophosphorylcholine; GSH, glutathione; HBF, human baby flora; 
LDL, low-density lipoproteins; βMCA, β-muricholic acid; SCFAs, short-chain fatty acids; 
TβMCA, tauro-β-muricholic acid; TCA, taurocholic acid; VLDL, very low-density 
lipoproteins. Figure from Martin et. al, 2007 [76].   
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Only free flavonoids without a sugar molecule (aglycones) were considered to be able to 
pass the gut wall, as there are no mammalian enzymes, capable of splitting the β-
glycosidic bonds [95]. It has been shown, that the final biological activity of flavonoids 
depends on the intestinal bacterial metabolism, capable not only of breaking the β-
glycosidic bonds, but also capable of biotransforming some of the flavonoic compounds, 
changing their bioactivity [96,97]. Equol was described as an important bacterial 
metabolite of daidzein [98]. Additionally equol was shown to have increased beneficial 
health effects compared to daidzein [99]. However, there is also a possibility for 
microbiome metabolism to convert daidzein into less active O-desmethylangolensin [100]. 
Inactive prenylated flavonoid, isoxanthohumol can be activated by intestinal microbiota into 
its active form, 8-pernylnaringenin [101]. Lignans are also polyphenolic compounds 
present in the human diet in high amounts [102]. Secoisolariciresinol, matairesinol, 
lariciresinol and pinoresinol are considered as being the most relevant dietary lignans 
[103-105]. Similarly to the flavonoic compounds, inactive plant lignans can be converted 
into mammalian lignans (enterolignans); enterodiol and enterolactone by intestinal 
microbiota [106]. Enterolignanas have estrogen-like biological properties, additionally 
interacting with various enzymes and proteins. Mentioned activities may result in e.g. 
protection against breast and colon cancer, and coronary heart diseases [107]. Microbial 
activation of flavonoids and lignans is shown to be dependent on the individual intestinal 
microbial community and activity [108]. Given the important role of hydrogen in the 
intestinal production of equol and enterolignans, the methane-producing and sulfate-
reducing bacteria seems to have a central position in this microbial biotransformation 
[97,109]. Equol production is also related to Clostridium coccoides-Eubacterium rectal 
cluster [108,110,111].              
Proteolysis and amino acids fermentation is related to the increase of phenolic compounds 
in the colon [112], which are usually absorbed and detoxified by glucuronide and sulfate 
conjugation in the mucosa of the bowel and in the liver. Afterwards, predominantly 4-
cresol, phenol and 4-ethylphenol [113] are excreted with the urine [114]. The production of 
phenolic compounds in mammals is associated with Clostridium, Bifidobacterium, 
Bacteroides fragilis and Escherichia coli and in many cases high concentrations in the 
urine are related to a variety of disease states in humans [115]. However, altered amount 
of these products were observed together with a change in the diversity of microbiota, 
Theoretical part 
23 
 
such as loss of Lactobacillus and Bacteroidetes species in case of inflammatory bowel 
disease and differences in the ratio of the Firmicutes and Bacteroidetes species in case of 
weight loss [116,117]. On the other hand, indole derivatives, also aromatic compounds, 
were associated with a positive impact on the GIT, such as protection against stress-
induced lesions, modulation of pro-inflammatory gene expression, increasing expression 
of anti-inflammatory genes and strengthening of epithelial cell barrier properties 
[71,118,119]. Additionally batch culture incubations with human fecal bacteria revealed the 
effect of pH, carbohydrate, protein, peptide and free amino acids availability on the 
production of phenolic and indolic compounds [115]. Results from this study showed that 
the type of substrate was an important factor limiting production of phenolic and indolic 
compounds. With protein (casein), the main end products of amino acid metabolism were 
phenol, phenylacetate, and phenylpropionate. Peptide fermentation of tryptic and peptic 
digests resulted in an increase in molar ratios of tyrosine dissimilation intermediates, with a 
reduction in phenylalanine fermentation. Indole was detected only when its free amino acid 
precursor was added to the system [115]. In the mammalian GIT amino acids are 
produced by the digestion of proteins and are mostly absorbed in the upper part of the 
intestines. However, in vitro studies show that some of the amino acids reach the lower 
part of intestines and may be used by bacterial flora as the source of nitrogen, leading to a 
production of SCFAs and gases in the colon. On the other hand, proline, threonine, 
asparagine and arginine were the only amino acids utilized by intestinal bacteria in the 
mentioned in vitro studies [120].    
Most primary amines are biosynthesized by decarboxylation from amino acids in the host 
cells. In the mammalian colon β-alanine, cadaverine, putrescine, tyramine and γ-
aminobutyric acid (GABA) are also known to be synthesized by colonic bacterial 
decarboxylase from free amino acids, aspartic acid, lysine, ornithine, tyrosine and 
glutamine, respectively [120]. Polyamines, such as putrescine, spermidine and spermine, 
are one of the most important metabolites produced by intestinal microbiota (Clostridium, 
Campylobacter and possibly Escherichia coli [71,120]), that affect the health and diseases 
of the host [121]. As organic cations, they are required for cell growth and differentiation, 
synthesis of DNA, RNA and proteins and they are absorbed as energy sources from the 
intestinal lumen [122]. Polyamines serve many functions, such as maturation and 
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maintenance of intestinal mucosal barrier, anti-inflammatory actions, anti-mutagenicity and 
autophagy [123-126].   
Vitamins are essential for normal cellular functions, growth and development and their 
deficiency leads to a variety of clinical abnormalities, which range from anemia to growth 
retardation and neurological disorders. Humans are not able to synthesize most of the 
vitamins and must obtain these micronutrients from exogenous sources. It has been 
recognized that gut bacteria, especially Bifidobacterium, are able to synthesize some of 
required vitamins, like vitamin K, B12, biotin, folate, thiamine, riboflavin and pyridoxine 
[71,127,128].  
Many other metabolites related to the intestinal microbiota (e.g. Bacteroides, 
Pseudobutyrivibrio, Ruminococcus, Lactobacillus), such as D-lactate, formate, methanol, 
ethanol, succinate, lysine, urea, etc were found to influence the mammalian host by direct 
or indirect synthesis or utilization of compounds or modulation of linked pathways 
[71,129,130]. Although there is a global understanding of metabolite flow across the 
microbiome-host-food web, for many reasons, including the difficulty in culturing many of 
the bacteria form the GIT, our knowledge of bacterial species synthesize which 
metabolites in vitro and co-metabolism between the intestinal species between each other 
is currently limited. However metabolic profiling as previously described offers an 
alternative strategy for characterizing GIT human and bacterial metabolites.
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3. Metabolomics in relation to pro-, pre- and syn-biotics 
3.1. Introduction to the pro-, pre- and sym-biotic concept 
Understanding of the gut microbiology in human health and nutrition has lead to rapid 
development of the number of pro-, pre- and sym-biotics. Recently, these supplements are 
aimed not only at the enhancement of well-being, but also as alternative or complementary 
treatments in acute and chronic diseases.  
3.1.1. Probiotics 
Probiotics are defined as “live microorganisms, which, when administered in adequate 
amounts, confer a health benefit for the host” [131]. The addition of probiotics to the 
intestine may optimize the balance of the intestinal microbiota by changing the intestinal 
pH and producing antimicrobial substances, such as bacteroicins, organic acids, and 
hydrogen peroxide [132-134]. The increase in beneficial bacteria results in competition 
with pathogenic bacteria for nutrients, potentially preventing acute diarrheas and 
pathogenic infections [135-137]. Animal and human studies have shown that probiotics 
may reduce intestinal permeability, provide nutrition and stimulate proliferation of the 
colonic cells and participate in the regulation of intestinal functions [138-140], protecting 
the host from colon cancer [141,142]. Additionally, probiotic bacteria have been shown to 
increase the host immunological barrier, preventing common infections (e.g. colds and 
fever), allergic disorders and inflammatory bowel diseases [143-147]. 
Bifidobacteria and lactobacilli are considered beneficial in the GIT microbiota and their 
prevalence is generally a good indicator of healthy, balanced microflora. Therefore, most 
of the microorganisms corresponding to the definition of probiotics are from bifidobacteria 
and lactobacilli genera. However, other microorganisms have also been tested for their 
probiotic properties. Probiotic microorganisms alone or in combination with each other are 
currently available as capsules or powders, or used in the production of various fermented 
products. Commonly used probiotic bacteria with documented clinical effects are given in 
Table 3.1. 
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Table 3.1   Probiotic bacteria with documented clinical 
effects. Table adapted from Santosa et. al, 2006 and 
Rouzaud, 2007 [132,148]. 
Bacteria Reference 
Bifidobacteria  
Bifidobacterium bifidum [149] 
B. breve Yakult strain [150] 
B. lactis Bb-12 [151] 
B. longum 913 [9] 
Lactobacilli  
Lactobacillus acidophilus NCFM [152] 
L. acidophilus LA-1 [153] 
L. acidophilus LB [154] 
L. casei immunitass DN114001 [155] 
L. casei Shirota YIT 0918 [156] 
L. gasseri [157] 
L. johnsonii  La1 [158] 
L. plantarum 299v [159] 
L. reuteri [160] 
L. rhamnosus GG (ATCC 53103) [161] 
L. bulgaricus [162] 
Other bacteria  
Enterococcus faecium [163] 
Escherichia coli Nissle 1917 [164] 
Streptococcus salivarius subsp. thermnophilus [165] 
Yeasts  
Sacchromyces boulardii  [166] 
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3.1.2. Prebiotics 
As previously mentioned, non-digestible dietary carbohydrates, which escape digestion in 
the upper part of the GIT, become available as growth substrates for the colonic 
microbiota. In the human diet the majority of these carbohydrates are plant cell wall 
polysaccharides, such as cellulose, arabinoxylan, xyloglucan, β-glucan, mannan, pectins 
and lignin [167,168]. However, it has been shown that only a certain types of bacteria have 
the enzymatic capability to utilize specific plant polysaccharides [169-173]. Therefore, 
beside the probiotic benefits, non-digestible dietary carbohydrates are another approach to 
confer the health benefits of intestinal beneficial bacteria by increasing the numbers of 
bifidobacteria and lactobacilli at the expense of other bacterial groups, additionally 
stimulating the saccharolytic activity in the colon [46].  
The concept of prebiotics is defined as ”selectively fermented ingredients that allow 
specific changes, both in the composition and/or activity of the gastrointestinal microbiota 
that confers benefits upon host well-being and health” [174]. According to this definition, 
inulin, fructo-oligosaccharides (FOS), galacto-oligosaccharides (GOS), trans-galacto-
oligosaccharides, gluco-oligosaccharides, soybean oligosaccharides, isomalto-
oligosaccharides, lactosucrose and lactulose have been classified as prebiotic substances 
[148]. Many studies focus on finding the new candidates to fulfill the requirements, namely 
focusing on gentio-oligosaccharides, chito-oligosaccharides, xylo-oligosaccharides (XOS), 
arabino-xylo-oligosaccharides, arabino-oligosaccharides, oligodextrans, pectic-
oligosaccharides, arabino-galacto-oligosaccharides, rhamno-galacturo-oligosaccharides, 
galacturonic-oligosaccharides and sialic acid oligosaccharides [148,174,175]. Selective 
stimulation of bifidobacteria and lactobacillus by non-digestible carbohydrates is affected 
by their chemical structure - type of glycosidic linkage, degree of branching and degree of 
polymerization (DP). Additionally, size of the carbohydrate influence where in the colon the 
fermentation occurs. Carbohydrates with low DP reach the proximal colon (Figure 2.2), 
where number of bacteria and substrate concentration is high. Non-digestible 
carbohydrates with high DP might reach the distal colon [176,177].  
The possible beneficial effects of prebiotics include the control of intestinal transit time and 
bowel habits, reduction of the risks of atherosclerosis, osteoporosis, obesity, type-2 
diabetes, cancer, infections and allergies. However, most studies providing information 
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about the beneficial effect of prebiotics are based on animal models and the effect in 
humans is still controversial [178]. 
3.1.3. Synbiotics 
The concept of synbiotics is a combination of probiotic and prebiotic approaches to confer 
benefits upon host well-being and health. A synbiotic aims at stimulating the growth and/or 
activity of beneficial intestinal microbes by using an appropriate non-digestible 
carbohydrate in conjunction with one or several probiotic strains [148]. Synergistic action 
of pre- and probiotics has been observed in animal studies with inulin and Bifidobacterium 
longum, trans-oligosaccharides and Bifidobacterium breve, FOS and Bifidobacterium [179-
181]. Clinical trials were performed with probiotic bifidobacteria and lactobacillus in 
combination with GOS, FOS and inulin, resulting in beneficial health effects on the 
participants, similar to the effects related to both dietary supplements [148]. Additionally, it 
has been postulated that prebiotics may provide protection of probiotics during intestinal 
transit and/or enhance their growth as well as that of the targeted commensal populations 
[182,183].      
 
3.2. Metabolic alterations induced by pro-, pre- and syn-
biotics in the host 
 
By changing the composition and functionality of the microbiota, co-metabolism between 
different bacteria and the host may also be affected. The impact of a functional food 
supplements on the function of the intestinal population is not fully understood. However, 
an increasing number of studies dedicated to the metabolic alterations induced by pro-, 
pre- and syn-biotics is slowly putting the pieces of the puzzle together. 
The metabolic effects of Lactobacillus rhamnosus and galactosyl-oligosaccharides given 
alone or as a synbiotic to mice colonized with human baby microbiota were studied by 
Martin et. al [184]. Acetate production was increased due to the stimulation of 
Bifidobacteria growth in presence of the prebiotic [7]. Altered transmethylation metabolic 
pathways were observed, interconnecting phosphocholine, betaine, dimethylgycine, 
sarcosine, choline, betaine and the formation of methionine from homocysteine, in liver 
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and pancreas. These results suggest that functional prebiotics might help with the 
metabolism homeostasis and detoxification processes [185,186]. This hypothesis is 
supported by the presence of carnitine and acetyl-carnitine in higher amounts in the 
urinary excertions [187,188]. Prebiotic supplementation has been shown to significantly 
reduce triglycerides in the liver, which could have an effect on the whole system lipid 
metabolism [189-192]. In the same studies, Lactobacillus rhamnosus supplementation 
resulted in changes of bacterial microflora. Metabolomic analysis showed the probiotic 
potential of lipoprotein reduction in the plasma as well as lower level of glutamine and 
glycogen [11]. Indirectly, the level of ascorbate in the body, a crucial cofactor for 
catecholamine biosynthesis, antioxidation and adrenal steroidogenesis might also be 
affected by the probiotic administration [193,194]. Supplementation of both Lactobacillus 
rhamnosus and galactosyl-oligosaccharides resulted in complementary effects of pro- and 
pre-biotics, at both bacterial and host metabolic levels. Bifidobacterial growth was 
increased more significantly than in case of the two supplements separately. From the 
methabolic point of view, as SCFAs were not affected compared to the prebiotics alone 
and a more significant reduction of liver triglycerides, kidney and plasma lipids was 
observed in case of synbiotic administration. Other studies done by Martin et. al [11,12] 
with a combination of Lactobacillus paracasei, L. ramnosus and two galactosyl-
oligosaccharide in the HBM mice, gave the similar results. The results showed changes in 
lipid profiles, gluconeogenesis, amino-acid and the methylamine metabolism associated 
with fermentation of carbohydrates by different bacterial strains.  
Studies presented by Martin et. al are performed in the animal model and the given results 
could differ in case of the human supplementation. On the other hand, studies focused on 
the synbiotics showed an increase in HDL and a decrease in LDL/HDL cholesterol in the 
clinical trials via administration of yogurt containing FOS, Bifidobacterium longum and 
Lactobacillus acidophilus [9]. Administration of similar synbiotic products to healthy 
individuals resulted in significant alterations of the metabolic activity of the intestinal 
microbiota [13]. Among more than 150 molecules occurring in the profile of fecal matter, 
amino acids and SCFAs were the most affected by the treatment. General increases in the 
SCFA content has been observed in parallel with a significant decrease of amino acids 
content, both in the aromatic (phenylalanine and tyrosine) and aliphatic regions. The 
significant decrease of amino acids, which was not substituted by the presence of their 
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toxic metabolites, such as ammonia and amines, suggests that the synbiotic food favored 
the amino acid assimilation rather than their catabolization. In fact the amino acids would 
not be required for energy due to the availability of FOS. Greater carbohydrate availability 
avoided the accumulation of toxic by-products of amino acid fermentation [195,196]. The 
increase of the SCFAs arises from the metabolism of FOS and amino acids. 
Significant increase in the common SCFAs production by the administration of GOS with 
Bifidobacterium breve and Lactobacillus casei was found in the infant [197]. Synbiotic food 
supplement in another human trial, containing FOS, Lactobacillus helveticus Bar13 and 
Bifidobacterium longum Bar33, was shown to not only increase the production of  SCFAs, 
but also ketones, carbone disulfate and methyl acetate in the fecal matter, that regulate 
cell proliferation, differentiation, anti-inflammatory and chemopreventative properties as 
well as detoxification processes [198].  
The presented studies show the breadth and the depth of gut microbiome modulation of 
host biochemistry and reveal that major mammalian metabolic processes are under 
symbiotic homeostatic control, with a probability to modulate via intake of the functional 
food supplements.   
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Aim of the study 
Lactobacillus acidophilus NCFM [1,2] colonization of germfree (GF) mice was carried out 
in order to map metabolites produced by the probiotic bacteria when growing in the 
intestinal environment, as well as host metabolites induced by the presence of the 
bacteria. In vitro experiments combined with the metabolomics methodology allow studies 
of metabolic mechanisms of NCFM’s effect on the host throughout the gut environment. 
The use of a metabolomic approach in the area of microbial activity in the gut is completely 
new. Only a small handful of very recent studies address the host metabolome as a 
function of colonizing bacteria [3,4]. However, recent literature suggests that the intestinal 
microbiota influence not only the faecal metabolome, but also the metabolite profiles of 
e.g. in biofluids and specific host organs [5-8]. Therefore, many different mammalian 
samples were investigated for the effect of the NCFM strain, comparing the metabolome of 
monocolonized (MC) mice to GF mice, in selected parts of the gastrointestinal tract. 
 
Materials and methods 
Lactobacillus acidophilus NCFM inoculation preparation 
Lactobacillus acidophilus NCFM was kindly provided by Danisco A/S. The strain was 
grown anaerobically at 37oC for 24h in de Man, Rogosa and Sharpe (MRS) broth (Oxoid 
Ltd., Basingstoke, Hempshire, England). After centrifugation at 3000g for 15min, pellets 
were washed and resuspended in a sterile saline supplement with 0.1% peptone. Final 
concentration of the NCFM cells in the inoculum was around 6.3·109 CFU/ml.     
 
Animal handling 
Animal experiments were conducted according to the Federation of European Laboratory 
Animal Science Associations (FELASA) and Danish legislation.  
Swiss Webster mice, bred at the National Food Institute (DTU Food), were originally 
obtained from Taconic (Lille Skensved, Denmark) and kept in germfree isolators. Absence 
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of colonizing bacteria in germfree mice was confirmed by cultivation of fecal samples. A 
monocolonized (MC) group of 5 male mice at age of 5 weeks was colonized with 200µl of 
previously described NCFM inoculum, resulting in around 109 cells per dosage. After the 
colonization, fecal samples from the MC mice were analyzed as described below in order 
to evaluate the efficiency of the NCFM colonization and stabilization in the GIT. A GF 
group of 5 male mice was also weaned at age of 5 weeks and kept germfree. Animals 
from both groups were terminated at age 8 weeks.  
 
Samples collection and metabolism quenching 
After utilization of the animals, blood was immediately taken by heart puncture, inserted in 
heparin tubes and centrifuged at 3000g for 15min, at 4°C. Plasma samples (supernatant) 
were frozen in the cryotubes using liquid nitrogen and kept at -80°C until further use.  
Samples from the oral cavity (tongue), liver and internal parts (lumen) of the jejunum, 
caecum and colon were taken from all the mice. The mucus layer of jejunum and caecum 
was obtained by washing lumen-free intestinal parts in sterile MQ water and separated 
from the tissue, using cell-scrapers. All samples were frozen in the cryotubes using liquid 
nitrogen and kept at -80°C until further use. Luminal samples from MC mice, were 
analyzed as described below to calculate the number of NCFM cells throughout the 
intestines 
 
Enumeration of bacteria 
Fecal and luminal samples from jejunum, caecum and colon of the MC mice were 
suspended in sterile saline supplemented with 0.1% of peptone. NCFM were counted on 
MRS agar (Oxoid Ltd., Basingstoke, Hempshire, England) after anaerobic incubation at 
37°C for 48h. Additionally, samples were screened for absence of contamination by plating 
on Luria-Bertani agar incubated at 37°C for 48h in an aerobic atmosphere. 
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Metabolites extraction 
All samples were shipped on dry ice to Auckland University where metabolite extraction 
was performed (by me). Prior to each extraction method, samples were defrosted on ice 
and kept cold throughout the whole procedure.  
Cold methanol and chloroform in a 1:1 ratio was added to the plasma samples in amounts 
proportional to the volume of the sample, meaning that 200µl of each solvent was added 
simultaneosly to the lowest plasma volume, increasing in amount accordingly to the 
sample volume. This ensured an equal proportion of water from plasma to methanol in 
each test. Tubes with the content were vortexed for 1 min and centrifuged at 4000g for 
5min at 4°C. Methanol and chloroform extracts were stored separately at -20°C until 
further use. 
Amounts of intestinal lumen and mucus were measured before each extraction. Samples 
were homogenized by grinding in the glass tubes kept on ice. 500µl of cold 80% methanol 
was added to the samples, vortexed for 1 min and centrifuged at 4000g for 5 min at 4°C. 
Methanol/water extracts were removed. This procedure was done 3 times, combining 
methanol/water extracts together for each sample. Afterwards, 500µl of cold chloroform 
was added to the sample, ultrasonificated for 1 min and centrifuged at 4000g for 5 min at 
4°C. Chloroform extract was separated from the biomass and, as well as the 
methanol/water extracts, stored at -20°C until further use. 
Weight of tissues (liver and part of the oral cavity) was measured before each extraction. 
Sample was homogenized by grinding in the glass tubes kept on ice. 2.5ml of cold 50% 
methanol and 2ml of chloroform was added to the sample.The mixtures were shaken for 
1h on ice, stored at 4°C and centrifuged at 4000g for 5 min also at 4°C. A methanol/water 
extraction was subsequently performed twice. Finally, both extracts were separated from 
the biomass and stored at -20°C until further use.  
Concentration of methanol in the polar extracts was decreased below 15%. 
Methanol/water extracts were freeze-dried and the chloroform ones dried under a nitrogen 
stream and kept at -20°C. Samples were secured with a silica gel to absorb the moist and 
shipped back to the Technical University of Denmark, LC-MS and DI-MS analyses were 
performed back in Denmark. 
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Metabolite detection 
The methanol/water extracts were resolubilized in 5 % acetonitrile (Fluka, Sigma-Aldrich, 
Steinheim, Germany), ultrasonicated for 10 min at 4°C and centrifuged at 10000 g for 7 
min at 4°C. The supernatant was removed and analysed by LCMS using a Dionex 
Ultimate 3000 RS liquid chromatigraph (Dionex, Germering, Germany) coupled to a Bruker 
maXis time of flight mass spectrometer equipped with an electrospray interphase (Bruker 
Daltonics, Bremen, Germany). Analytes were separated on a Kinetex pentafluorophenyl 
column 100 x 2.10 mm, 2.6 µm, 100Å (Phenomenex, USA), using the solvent system: A (5 
mM ammonium formate with 0.1% formic acid; both from Fluka, Sigma-Aldrich, Steinheim, 
Germany), and B (acetonitrile, Fluka, Sigma-Aldrich, Steinheim, Germany, with 0.1 formic 
acid). Solvent programming was isocratic 0% B for 2 min followed by 5% at 5 min, then 
linear gradient up to 100% B at 10 min and 100% B at 12 min. The solvent composition 
was returned to initial conditions at 12.1 min and recalibrated to 14 min. Flow rate was 0.3 
ml/min. The oven temperature was 40°C. Injection volumes were 3 µL. The following 
electrospray interphase settings were used: nebulizer pressure 2 bar, drying gas 10 L/min, 
200°C, capillary voltage 4500V. Scan range was from 100 to 1000 m/z. Samples were 
analyzed in both positive and negative mode. External and internal calibration was done 
using sodium formate clusters (Sigma-Aldrich, Steinheim, Germany). Lock-mass 
calibration (hexakis(1H,1H,2H-perfluoroetoxy)phosphazene, Apollo Scientific, Stockport, 
UK) was applied in order to lower the measurement error to minimum. 
Chloroform extracts were resolubilized in 80 % methanol (Fluka, Sigma-Aldrich, Steinheim, 
Germany) with 0.1 % (vol/vol) formic acid, ultrasonicated for 10 min at 4°C and centrifuged 
at 10000g for 7 min at 4°C. The supernatant was removed and analysed by DI-MS, as 
follows: 1 µl was injected into 0.25 ml/min flow of 80 % acetonitrile, which was introduced 
directly into the electrospray ionsource. The mass spectrometer with the electrospray 
interphase settings were the same as described before. Scan range was from 100 to 1000 
m/z. Data was acquired for 2 min for each sample. Samples were analyzed in both positive 
and negative mode. External calibration was done using sodium formate clusters (Sigma-
Aldrich, Steinheim, Germany). 
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Multivariate data analysis 
The differences in metabolite profiles were evaluated by principal component analysis 
(PCA). LC-MS data in negative was grouped into buckets according to the mass to charge 
ratio (m/z; Da) and retention time (RT; min). Size of each bucket was 1 Da and 1 min, from 
0.5-5 min and m/z 100-1000 Da. Data was mean centred and normalised by the sum of 
bucket. PCA models were calculated using Profile Analysis 2.0 (Brucker Daltonics, 
Bremen, Germany).  
 
Preliminary results 
During 3 weeks of incubation, numbers of Lactobacillus acidophilus NCFM in the MC mice 
were stable, approximately 109 CFU/g of faeces (Figure 1). Luminal samples differed in 
the number of bacteria, gradually increasing from the jejunum to colon (Figure 2).     
Studies focussed on the full metabolome, extracting polar and non-polar metabolites. Initial 
PCA analysis of the LC-MS data in negative mode showed a distinct difference between 
most of the samples from GF and MC mice (Figures 3, 4, 5B, 6, 7), indicating that the 
NCFM strain had an impact on the region-dependent metabolome of the mammalian host 
as well as global one (liver and plasma samples; Figs. 6 and 3). However, mucus samples 
from the jejunum did not show any grouping of the data (Figure 5A). This may be because 
the amount of biomass from the jejunal mucus available for the metabolite extraction was 
very low. This could have caused lack of separation between the groups, at least in the 
negative mode of LC-MS.  
Data buckets for the luminal samples showed significant similarities in the metabolic profile 
of caecum and colon (Figures 4B and 4C). The same metabolites seemed to be causing 
the group separations in both cases for the LC-MS data in negative mode. Similarly, 
numbers of bacteria in the lumen from caecum and colon were very similar (Figure 2) in 
the MC mice. Some of the buckets were present in all of the luminal samples (Figure 4).  
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Preliminary conclusions and remaining work 
Preliminary studies showed a good indication of the influence of the NCFM strain on the 
metabolome of the host. However, PCA analyses of the LC-MS data in positive mode, DI-
MS data in both, positive and negative modes are still required. After selecting the buckets 
responsible for the group separation, P-values for selected buckets will be calculated. 
Metabolite identification and confirmation will be done for compounds with P-values lower 
than 0.05, comparing intensities from GM and MC samples.    
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Figures 
 
Figure 1 NCFM number as log10CFU in faecal samples of MC mice. 
 
 
Figure 2 NCFM number as log10CFU in luminal samples from jejunum, caecum and colon of 
MC mice. 
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Figure 3 PCA score (left) and loading (right) plot of the LCMS data in negative mode. 
Presented on the score plot plasma samples from GF (∆) and MC (o) mice. Numbers on the 
loading plot refer to the data bucket as mass to charge ratio (m/z; Da) per retention time (RT; min). 
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Figure 4 PCA score (left) and loading (right) plot of the LCMS data in negative mode. 
Presented on the score plots lumen samples from jejunum (A), caecum (B) and colon (C) of GF (∆) 
and MC (o) mice. Numbers on the loading plot refer to the data bucket as mass to charge ratio 
(m/z; Da) per retention time (RT; min). 
B 
C 
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Figure 5 PCA score (left) and loading (right) plot of the LCMS data in negative mode. 
Presented on the score plots mucus samples from jejunum (A) and caecum (B) of GF (∆) and MC 
(o) mice. Numbers on the loading plot refer to the data bucket as mass to charge ratio (m/z; Da) 
per retention time (RT; min). 
A 
B 
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Figure 6 PCA score (left) and loading (right) plot of the LCMS data in negative mode. 
Presented on the score plot liver samples from GF (∆) and MC (o) mice. Numbers on the loading 
plot refer to the data bucket as mass to charge ratio (m/z; Da) per retention time (RT; min). 
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Figure 7 PCA score (left) and loading (right) plot of the LCMS data in negative mode. 
Presented on the score plot oral cavity samples from GF (∆) and MC (o) mice. Numbers on the 
loading plot refer to the data bucket as mass to charge ratio (m/z; Da) per retention time (RT; min). 
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Abstract 
Prebiotic oligosaccharides are defined by their selective stimulation of growth and/or 
activity of bacteria in the digestive system in ways claimed to be beneficial for health. 
However, apart from the generation of short chain fatty acids, little is known about bacterial 
metabolites created by prebiotic fermentation, and the impact of the size (chain length) of 
the oligosaccharides remains largely unstudied.   
We carried out in vitro fermentations in human fecal microbial communities (derived from 
six different individuals), using high-mass (HA, >1kDa), low-mass (LA, <1kDa) and mixed 
(BA) sugar beet arabino-oligosaccharides (AOS), respectively, as carbohydrate sources, 
and including fructo-oligosaccharides (FOS) as control. Changes in the bacterial 
communities and the metabolites produced were analyzed by qPCR and LC-MS, 
respectively.  
Microbial response to the carbohydrates was highly dependent on the individual microbial 
ecosystem. All tested carbohydrate sources resulted in a significant increase of 
Bifidobacterium spp. between 1.79 fold (HA) and 1.64 fold (FOS) in the microbial 
populations after fermentation. Additionally, HA and FOS fermentation caused a decrease 
in levels of Desulfovibrio spp. 
HA caused the highest increase of metabolites putatively beneficial to human 
gastrointestinal health. Fermentation of AOS, and in particular of HA, additionally resulted 
in an increase of various bacterial metabolites that may potentially be involved in 
biosynthetic pathways of epithelial cells when produced in vivo in the gut. In all six fecal 
communities, the HA fraction gave a metabolic response that was more similar to the 
established prebiotic FOS than seen for the LA and BA fractions.             
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Introduction 
The human gastrointestinal tract (GIT) produces a large amount of enzymes capable of 
hydrolyzation of various disaccharides and a few specific polysaccharides (starches). 
However, most complex oligo- and polysaccharides including e.g. arabino- and fructo-
oligosaccharides cannot be degraded by the human digestive enzymes. These substrates 
may instead be metabolized by the very diverse ecosystem of bacteria inhabiting the 
human gut [1].  
Prebiotic oligosaccharides are non-digestible oligosaccharides defined by their selective 
stimulation of growth and/or activity of bacteria in the digestive system in ways claimed to 
be beneficial for health [2].  
Inter-bacterial interactions, as well as interactions between bacteria and host are based on 
a variety of mechanisms. Biochemical messages can be sent by simple or complex abiotic 
molecules as well as by genetic sequences [3]. Previous studies of prebiotic degradation 
were mainly focused on bacterial production and epithelial absorption of short chain fatty 
acids (SCFA) [4-6]. A more exhaustive approach is metabolomic footprinting, which 
describes the bacterial exometabolome, defined as the pool of molecules excreted by a 
bacterial community into the surroundings [7]. Such molecules are likely to be involved in 
signaling between bacteria or to the host. Metabolomics has previously been found useful 
in studies of the intestinal microbial ecosystem [8,9] 
The aim of the present study was to evaluate the potential prebiotic effect of sugar beet 
arabino-oligosaccharides (AOS) in comparison to the established prebiotic fructo-
oligosaccharide (FOS) [10,11]. We addressed whether in vitro fermentation of differently 
sized AOS molecules caused different changes in intestinal bacterial communities isolated 
from six healthy humans. Additionally, the putatively prebiotic (health-promoting) effect of 
AOS was addressed using a new approach: Metabolomics. 
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Materials and Methods 
Arabino-oligosaccharide substrates 
Sugar beet arabino-oligosaccharides (AOS) were obtained from Danisco A/S (Nakskov, 
Denmark). The arabino-oligosaccharides were derived from a liquid side stream from the 
ultrafiltration and diafiltration step in the sequential acid extraction of pectin with nitric acid 
from sugar beet pulp, involving removal of insoluble cellulose, ultrafiltration, and 
diafiltration with a 50 kDa cutoff [12]. The pulp was dried prior to extraction. 
Separation of arabino-oligosaccharides from the base solution of arabino-oligosaccharides 
(BA) according to size was performed in a 200mL stirred membrane reactor model 8200 
(Millipore, Billerica, MA) equipped with a 1 kDa MWCO regenerated cellulose membrane 
(Millipore, Billerica, MA) connected to compressed nitrogen for flux regulation. Filtration 
was performed at room temperature. Filtration was performed at 3 bar until the retentate 
volume was 30% of the sample volume, and followed by diafiltration in one sample volume 
of deionized water. The permeates enriched in low molecular weight oligosaccharides 
were denoted LA and the retentate enriched in high molecular weight oligosaccharides 
were denoted HA. Free sugar content and monosaccharide composition was determined 
by acid hydrolysis and HPAEC as described previously [11]. 
 
Size exclusion 
HPSEC was performed using a P680 HPLC pump, an ASI-100 automated sample injector, 
and an RI-101 refractive index detector (Dionex Corp., Sunnyvale, CA). Samples were 
separated on a Shodex SB-806HQGPCcolumn (300 x 8mm) with a Shodex SB-G guard 
column (50 x 6 mm) from Showa Denko K.K. (Tokyo, Japan) with 100 mM sodium acetate 
pH 6 as mobile phase used with a flow rate of 0.5 mL/min. Temperature was maintained at 
40 °C. Data were collected and analyzed with the program Chromeleon 6.80 SP4 Build 
2361 software (Dionex Corp., Sunnyvale, CA). 
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Removal of monosaccharides from the Semi Synthetic Substrates 
In order to reduce the amount of monosaccharides present in the AOS-based substrates, 
we carried out an initial bacterial fermentation using L. acidophilus NCFM. This strain was 
kindly provided by Danisco A/S and chosen because we have previously mapped the 
metabolites consumed and produced by this strain [13], and because it’s genome 
sequence [14] does not contain the enzymes needed for AOS degradation.  
L. acidophilus colonies were grown anaerobically at 37oC overnight in MRS broth (Oxoid 
Ltd., Basingstoke, Hempshire, England) and dissolved 107 times into Semi Synthetic 
Medium (SSM) [15] containing 1% glucose. After 7 hours of resulting in 105.8 CFU/ml of L. 
acidophilus NCFM, the cultures were diluted 100 fold into SSM containing either 1% 
glucose (control), 20 g/L of BA, 20g/L LA, or 20g/L HA. After 24h of anaerobic incubation, 
removing non-arabinan monosaccharides from the media, the cultures were centrifuged at 
3000g for 5min at 4°C, whereafter, supernatants were sterile filtrated in order to remove 
remaining L. acipdophilus cells and kept in at 4°C until further use. The final concentration 
of the arabinan oligosaccharides was estimated to 10 g/L. 
 
Subjects and fecal sample collection 
Fecal samples were obtained from six healthy volunteers (four women and two men). 
None of the participants had been treated with antibiotics for at least 3 months before 
enrolment and had no history of gastrointestinal disorder. The mean age of the participants 
was 41±9 years. The samples were collected in airtight containers at home by the 
participants and stored at 4°C (limited storage time was encouraged [16]) until delivery to 
the laboratory, where they were processed immediately. The fecal samples were 
homogenized in 50 % glycerol (1:1 dilution) in an anaerobic cabinet (Macs Work Station, 
Don Whitley) containing 10% H2, 10% CO2, and 80% N2, and stored at -80°C until further 
analysis, as described below. 
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In vitro fermentation by human fecal bacterial communities 
Fermentation studies were carried out to assess the effect of BA, LA and HA on the 
microbial composition and activity in human fecal samples, while parallel incubations with 
the established bifidogenic substrate FOS [17] and no carbohydrates, respectively, were 
used as controls. Fecal samples prepared as described above were defrosted in an 
anaerobic cabinet and 10% (w/v) fecal slurry was prepared by mixing the samples with 
anoxic PBS (Oxoid, Greve, Denmark) immediately before fermentation. 
Sterile SSM supernatants prepared as described above were mixed 1:1 with sterile 
minimal basal medium containing 2 g/L of peptone water (Oxoid Ltd., Basingstoke, 
Hempshire, England), 1 g/L of yeast extract (Sigma Chemical co., St. Louis, Missouri, 
USA), 0.1 g/L of NaCl (Merck KGaA, Darmstadt, Germany), 0.04 g/L of K2HPO4 (Merck 
KGaA, Darmstadt, Germany), 0.04 g/L of KH2PO4 (Merck KGaA, Darmstadt, Germany), 
0.01 g/L of MgSO4.7H2O (Merck KGaA, Darmstadt, Germany), 0.01 g/L of CaCl2.2H2O 
(Merck KGaA, Darmstadt, Germany), 2 g/L of NaHCO3 (Merck KGaA, Darmstadt, 
Germany), 0.5 g/L of L-cysteine hydrochloride (Sigma Chemical co., St. Louis, Missouri, 
USA), 50 mg/L of hemin (Sigma Chemical co., St. Louis, Missouri, USA), 10 μl/L of vitamin 
K1 (Sigma Chemical co., St. Louis, Missouri, USA), 0.05 g/L manganese sulfate 
monohydrate ( Merck KGaA, Darmstadt, Germany) and 1 mL/L of Tween 80 (VWR, 
Darmstadt, Germany). The pH of the final solution was adjusted to 7. Estimated (not 
accurate) concentrations of AOS were 5 g/L. Positive controls were made by adding 5 g/L 
of FOS to the SSM supernatant prepared by NCFM fermentation of glucose, and negative 
controls by adding nothing to the same SSM supernatant. All solutions were reduced over 
night in an anaerobic cabinet and inoculated with fecal slurry prepared as described above 
to a final concentration of 1% feces. Tube caps were loosely placed on the vials to allow 
gas exchange but avoid evaporation. Each fermentation was carried out in triplicates for 
each fecal community, carbohydrate source and controls. The fermentation was non-pH 
controlled and non-stirred due to the low reaction volume (6-7 mL) and was carried out in 
an anaerobic cabinet at 37°C. At the beginning of the fermentation (time 0), and after 24 
hours (time 24), 1 ml samples were taken and centrifuged at 3000 g for 15 min at 4°C. The 
supernatants were used for metabolite profile analysis and the pellets were used for 
extraction of bacterial DNA as described below.  
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Extraction of bacterial DNA 
DNA was extracted from each of the triplicate fermentation samples using the QIAamp 
DNA Stool mini kit (Qiagen, Hilden, Germany) with preceeding bead beating as previously 
described [18]. The concentration of the purified DNA was measured by Qubit® 2.0 
Fluorometer (Invitrogen) and the DNA was stored at -20°C until use. 
 
Real-Time PCR assay  
Amplification and detection of purified bacterial DNA by Real-time PCR was performed 
with the ABI Prism 7900 HT from Applied Biosystems using optical grade 384-well plates. 
Each amplification reaction was done in duplicate for each of the triplicate fermentation 
samples in a final volume of 11 μl containing; 5.50 μl SYBR® Green Master Mix (Applied 
Biosystems, Denmark), 200 nM of each of the primers (Eurofins MWG Synthesis GmbH, 
Ebersberg, Germany), 2 μl template DNA (1 ng/µL), and Nuclease-free water purified for 
PCR (Qiagen). The amplification program comprised one cycle at 50°C for 2 min; one 
cycle at 95°C for 10 min; 40 cycles at 95°C for 15 sec.; 60°C for 1 min, and finally one 
cycle of melting curve analysis for amplicon specificity at 95°C for 15 sec, 60°C for 20 sec. 
and increasing ramp rate by 1.92°C/min until 95°C for 15 sec. The qPCR data was 
baseline corrected and N0-values, representing initial concentrations of the specified 16S 
rRNA genes, were calculated using the LinRegPCR software (version 11.1, based on 
Ruijter et al. [19]). All results were calculated as means of duplicate N0 estimations, equal 
values required. The relative quantities of gene targets encoding 16S rRNA sequences of 
the bacterial taxa were calculated using N0 (bacterial target)/N0 (total bacterial population). 
The applied specific 16S rRNA-targeting primers are listed in Table S1 (supplementary 
data). Prior to quantification, all primers were tested to confirm sensitivity and specificity 
using DNA from pure bacterial species (A. Bergström, T.R. Licht, A. Wilcks, J. B. 
Andersen, L. R. Schmidt, H. Grønlund, L. K. Vigsnæs, K. F. Michaelsen and M.I. Bahl, in 
press) 
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Metabolism quenching 
Time 0 and time 24 supernatants from the fermentations were quickly transferred into cold 
methanol (Fluka, Sigma-Aldrich, Steinheim, Germany, stored at -80°C) in the ratio 1:1 to 
quench the metabolism. Samples were stored at -80°C and centrifuged at 15000g for 5 
min at 4°C just before LCMS (Liqiud Chormatography – Mass Spectrometry) analysis was 
carried out as described below. 
 
Metabolite detection by LCMS 
Metabolite analysis was conducted using a Dionex Ultimate 3000 RS liquid chromatograph 
(Dionex, Germering, Germany) coupled to a Bruker maXis time of flight mass 
spectrometer equipped with an electrospray interphase (Bruker Daltonics, Bremen, 
Germany). Analytes were separated on a Kinetex pentafluorophenyl column 50 x 2.10 
mm, 2.6 µm, 100Å (Phenomenex, USA), using the solvent system: A (10 mM ammonium 
formate at pH 3.5), and B (acetonitrile). Solvent programming was isocratic 0% B at 0 min 
followed by a linear gradient up to 100% B at 7 min and 100% B at 8 min. Flow rate was 
0.25 mL/min at 0 min, and increased to 0.4 mL/min at 7 min. Solvent composition and flow 
were returned to initial conditions at 8.2 min. The oven temperature was 40°C. Injection 
volumes were 1 µL. The following electrospray interphase settings were used: Nebulizer 
pressure 2 bar, drying gas 10 L/min, 200°C, capillary voltage 4000V. Scan range was from 
50 to 800 m/z. Samples were analyzed in both positive and negative mode. External and 
internal calibration was done using sodium formate clusters (Sigma-Aldrich, Steinheim, 
Germany). Lock-mass calibration (hexakis(1H,1H,2H-perfluoroetoxy)phosphazene, Apollo 
Scientific, Stockport, UK) was applied in order to lower the measurement error to 
minimum. MSMS fragmentation of the selected masses (Tables 3 and 4) was done with a 
collision energy at 14 eV at mass 100 ramped lineary to 20 eV at mass 500 and to 30 eV 
at mass 1000. 
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Metabolite identification 
Metabolite identification was based on the exact mass to charge ratio (m/z) with a very low 
measurement error, MSMS fragments (Tables 3 and 4), metabolites found in the Human 
Metabolome Database (HMDB; [20]) and the Metabolite Mass Spectral Database 
(METLIN; [21]) where MSMS spectra of some selected metabolites are present, and 
references to the bacterial metabolism presented in the discussion part of this paper.   
 
Statistical analysis of the PCR data 
Statistical analysis of the qPCR data was performed with the GraphPad Prism software 
(version 5.03; GraphPad Software Inc., La Jolla, CA). One-way analysis of variance and 
Tukey's multiple comparison tests were used to determine significant differences in the 
density of selected bacterial taxa in the different fermentations (NC, FOS, BA, LA and HA). 
Homogeneity of variance was assessed using Bartlett's test for equal variances. Log-
transformations were performed before statistical analysis of qPCR measurements that did 
not meet this criterion. The nonparametric Kruskal-Wallis test and Dunn's multiple 
comparison tests were used for datasets, which did not have homogeneity of variance 
even after log-transformation. Tests were considered statistically significant when P-values 
lower than 0.05 were obtained. 
 
Multivariate data analysis 
PCA analysis 
LCMS data were grouped into buckets of 1 min and 1 m/z differences in the range from 
0.5 to 9 min and 50 to 800 m/z and normalized by the sum of buckets in the analysis by 
use of Profile Analysis 2.0 (Brucker Daltonics, Bremen, Germany).  
The next step of the data analysis was done in Excel. A set of equations, presented below, 
was used to select metabolites present in the medium after 24h and produced exclusively 
due to the addition of the given carbohydrate.  
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First, the metabolites which were present already before the fermentation (CH0), were 
subtracted from the metabolites present after 24 hours of fermentation (CH24), and the 
remaining metabolites were represented as an average value CH(A) of intensities of the 
given bucket in three independent fermentations (I, II and III): 
CH24(I)- CH0(I) = CH(I); if CH(I) ≤ 0, then CH(I) = 0; (CH(I) + CH(II) + CH(III))/3 = CH(A)  
Secondly, the average amount of specific metabolites NC(A) produced only due to 
metabolism of the basal medium were identified by analysis of the control incubations (NC) 
carried out without addition of a carbohydrate source: 
NC24(I)- NC0(I) = NC(I); if NC(I) ≤ 0, then NC(I) = 0; (NC(I) + NC(II) + NC(III))/3 = NC(A) 
Finally, the metabolite values M(A) to be included in the Principal Component Analysis 
(PCA) were calculated as: CH(A) – NC(A) = M(A); If M(A) ≤ 0, then M(A) = 0 
 
P-values describing differences between the experiments carried out with different 
substrates were calculated by t-test. PCA plots made in LatentiX 2.10 were based on the 
metabolite buckets showing significant differences between the tested carbohydrate types 
(P-value < 0.05; data not shown). Data were mean centered to avoid the influence of 
LCMS noise on the model and normalized (2-norm). From the positive mode, due to the 
presence of TWEEN in the medium, which was necessary for growth of lactobacilli, all m/z 
buckets at 3 min, 4 min and 7 min were removed. From the negative mode buckets with 
mass 555.5, 665.5, 666.5 (lock mass), 187.5, 188.5 and 189.5 at all time buckets were 
disregarded due to the noise they were creating.  
Selected metabolites from previous PCA plots were used together with the PCR data 
(before log-transformation) to create a PCA plot (Figure 6) in LatentiX. Data was 
autoscaled and normalized (2-norm).   
 
Statistical analysis of the LCMS data 
Heat maps were created to illustrate the P-values of differences between levels of selected 
metabolites present before and after fermentation, taking into consideration only 
metabolites which increased during fermentation. P-values were calculated using t-test in 
Excel. Data used in this analysis were normalized by the sum of buckets by use of Profile 
Analysis 2.0. 
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Results 
Oligosaccharide composition 
Size exclusion chromatography (Figure 1) showed that the base solution of arabino-
oligosaccharides (BA) had a dual distribution with one peak at 24.7 minutes corresponding 
to monomers and a larger broader peak around 1.0 kDa corresponding to the 
oligosaccharides. The low molecular weight fraction (LA) showed a similar profile, but with 
a tendency towards a lower content of oligosaccharides below 1.0 kDa. The high 
molecular weight fraction (HA) showed one homogeneous peak around 1.0 kDa with only 
a minor peak at 24.7 minutes indicating that the monosaccharide content was significantly 
reduced, but not removed completely. The BA substrate contained relatively high amounts 
of monosaccharides, mainly glucose (13.3% w/w), arabinose (10.1% w/w) and fructose 
(8.0% w/w). Other pectin derived free sugars like rhamnose, galacturonic acid, galactose, 
and fructose was found in minor amounts (2.3% w/w in total). Acid hydrolysis revealed that 
the residual 66.3% of the substrate was comprised of arabino-oligosaccharide moieties. 
The relative high content of monosaccharides compared to analysis of similar substrates 
[11,20] might be due to the drying of the pulp prior to the acidic extraction. LCMS analysis 
of the BA fraction revealed several peaks besides those identified by comparison to linear 
arabino-oligosaccharides, which indicated that the arabino-oligosaccharides applied in this 
study to a large extent were branched (data not shown). Initial fermentation with 
Lactobacillus acidophilus NCFM removed a significant amount of the non-arabinan 
monosaccharides present in the arabino-oligosaccharides fractions, as detected by LCMS 
(data not shown). 
 
Real-Time PCR studies of bacterial community composition 
After fermentation in fecal slurries obtained from six different healthy subjects, quantitative 
PCR was applied to measure the density of gene targets encoding 16S rRNA of selected 
bacterial taxonomic units. The ability of the substrates to selectively stimulate the growth of 
a given bacterial taxon was compared to that of the NC (No added Carbohydrate) 
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fermentations (Table 1 and Figure S1). The fecal communities fermented on BA, LA and 
HA selectively increased the relative abundance of Bifidobacterium spp. significantly 
(P<0.01, P<0.001, and P<0.001, respectively) when compared to the NC fermentations. 
The densities of bifidobacteria after fermentation of BA, LA and HA were however not 
significantly different from the densities obtained by fermentation of FOS, which is 
considered to be the “golden standard” within the field of prebiotics. Also the densities of 
Lactobacillus spp. were higher in the BA, LA, HA and FOS fermentations than in the NC 
samples, although this was not statistically significant (P=0.18, P=0.21, P=0.16 and 
P=0.23, respectively). The relative abundances of the C. coccoides group and Alistipes 
spp. were significantly lower in fecal communities fermented on LA than in the NC 
fermentations (P<0.05 and P<0.05, respectively). FOS fermentation resulted in a 
significantly lower relative abundance of Alistipes spp. and Desulfovibrio spp. than the NC 
fermentations (P<0.05 and P<0.05, respectively). A significantly lower density of 
Desulfovibrio spp. was additionally observed in the fecal communities fermented on HA 
(P<0.01). No statistical difference in bacterial density after fermentation of the four different 
substrates was seen for the remaining investigated bacterial taxa.  
Major individual differences between intestinal bacterial ecosystems derived from different 
subjects were expected to occur. The density of 16S rRNA genes of four different bacterial 
taxonomic units, showing alteration after fermentation (Bifidobacterium spp., C. coccoides 
group, Alistipes spp. and Desulfovibrio spp.), were thus determined for each of the six 
individual fecal communities (Table 2). Substantial individual differences were observed 
depending on substrate and bacterial target. However, fermentations in all of the six 
intestinal communities resulted in significantly higher increases of bifidobacteria than 
measured in the NC samples. When comparing of the amount of increase caused by the 
three substrates (BA, LA and HA), it varied significantly among the six fecal community. 
FOS fermentation resulted in significantly lower fold changes of bifidobacteria in three out 
of the six fecal communities than seen for the arabino-oligosaccharide based substrates. 
Only one fecal community (derived from individual 2) showed no significant difference in 
bifidobacterial increase caused by the tested substrates. The densities of the C. coccoides 
group were either unaltered or significantly lower after fermentation either of the four 
substrates. However, fermentation of FOS generally caused less decrease of C. coccoides 
than observed for BA, LA and HA. In all six bacterial communities, densities of Alistipes 
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spp. and Desulfovibrio spp. were either unaltered or significantly lower after fermentation 
of either of the four substrates, however the level of decrease varied between 
communities.  
 
Metabolomic studies 
After quenching the metabolism, LCMS analysis of samples taken before and after 
fermentation was done in positive and negative mode. Only buckets where significant 
differences were observed between at least 2 substrates were included in the further 
analysis, which significantly reduced the amount of variables (metabolites). PCA analysis 
of metabolite data (Figures S2 and S3) from positive mode showed, that lack of metabolite 
profile clustering was clearly affected by bacterial source communities and that 
differentiation caused by fermentation substrate was therefore unclear. However, in the 
negative mode, FOS-fermentation samples clustered separately from all three types of 
arabino-oligosaccharides (Figure S3). For each of the bacterial communities, we observed 
that BA and LA metabolite profiles were typically very similar to each other, but different 
from the profiles measured after fermentation of HA or FOS. 
In order to identify effects of the fermentation substrates on the metabolome and avoid 
masking caused by the differences between the individual bacterial communities PCA 
analysis was carried out for each community separately and presented as bi-plots (Figures 
2 and 3). Based on this, metabolites causing the differences between samples fermented 
on the four substrates were chosen (Tables 3 and 4, Figure 4). The above described 
observation that profiles obtained after BA and LA fermentation were typically similar to 
each other, but different from HA and FOS fermented samples, was also true in the PCA 
plots based on the individual bacterial communities. In general, the metabolite contents of 
FOS fermented samples were more different from all three samples based on arabino-
oligosaccharide fermentation, than these three samples were from each other.  
Phenylalanine (Figure 2; No. 1; all individuals), xanthine (Figure 3; No. 18; B2, B3, B5 and 
B6) and linoleic acid or its derivative (Figure 3; No. 21; B1, B4 and B6) contributed 
significantly to the difference between arabino-oligosaccharide and FOS-fermented 
samples. In all six microbial communities, phenylalanine (1) was present in higher 
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amounts in one or more of the AOS-fermented samples than in FOS-fermented samples. 
Metabolites which were present in high levels in FOS and HA fermentation samples, but 
separated these from BA and LA fermentations, were N’-acetylspermidine (Figure 2; No. 2; 
B1, B2, B3, B5 and B6), phenyllactic acid (Figure 3; No. 19; B2, B3, B4, B5 and B6) and a 
flavonoid (Figure 3; No. 16; B2, B3, B4, B5). A significant increase of N’-acetylspermidine, 
phenyllactic acid and flavonoid was observed in all subjects after fermentation of one or 
more of the 4 oligisaccharides (Figure 4), however, in general the highest increase of this 
metabolite was in HA and FOS. BA and LA fractions seems to stimulate production of 
cysteine (Figure 2; No. 6; B1, B3, B5 and B6), aminobenzoic acid (Figure 2; No. 8; B1, B4 
and B5), hypoxanthine (Figure 2; No. 9; B2, B3, B4 and B6) and 3-oxooctadecanoic acid 
(Figure 2, No. 11; B3, B5, B6 and Figure 3; No. 17; B2, B3, B5, B6). PCA plots also 
showed a positive correlation between 3-oxoalanine (Figure 2; No. 4; B1, B2, B3, B5, B6), 
tyramine (Figure 2; No. 5; B1, B2; B3; B5, B6), homoveratic acid (Figure 3; No. 13 B1, B2; 
B3; B5, B6); and arabionofuranosyl structures (Figure 3; No. 15; B1, B2, B3, B4 and B5) 
with the presence of high molecular weight arabino-oligosaccharides (HA). Unspecified 
metabolite (Figure 2; No. 7; B1, B2, B3, B4, B5), (R)-3-hydroxy-octadecanoic acid (Figure 
2, No. 12; B4, B5, B6), fatty acid derivatives (Figure 3, No. 14 and 20; all individuals) and 
allantoic acid (Figure 3; No. 22; B3, B4, B6) were mostly correlated to FOS, however this 
could not be confirmed by P-value calculations (Figure 4). Presence of iso-valeraldehyde 
and oleamide (Figure 2, No. 3 and 10 respectively) depended highly on the bacterial 
community.  
 
Combined analysis of bacteria and metabolites 
A PCA analysis was conducted for combined LCMS and PCR data. A loading plot 
combining selected metabolites (Table 3 and 4) with all targeted bacteria taxa (Table 1) 
was created (Figure 5) in order to reveal correlations between the presence of specific 
bacteria and specific metabolites. 
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Discussion 
Previous in vitro studies with sugar beet arabino-oligosaccharides (AOS) have showed 
their bifidogenic effect and influence on the gastrointestinal microflora [10,11]. Our present 
results confirmed that AOS, whether it was high molecular weight (HA), low molecular 
weight (LA), or a mix of these (BA) selectively stimulated the growth of bifidobacterial 
species (Table1 and 2), which are associated with positive effects on the host health [22-
24]. Another potentially positive aspect of the microbiota modulation was a decrease of 
Desulfovibrio spp. (Table 1 and 2), which were seen after both FOS and HA fermentation. 
This species belongs to the sulfate reducing organisms, which are suggested to play a role 
in inflammatory bowel diseases (IBD) due to the toxic effects of sulphide on colonic 
epithelial cells [25-29]. Additionally, an increased abundance of bacterial species within the 
genus Allistipes has been correlated with a greater frequency of pain in patients with IBD 
[30], while we found that the amount of Allistipes spp.was reduced by fermentation of LA 
and FOS. Most of the measured bacterial taxa were not affected by fermentation of AOS 
or FOS (Table 2). As also observed for the measured bacterial taxa (Figure S1), the 
metabolite profile resulting from fermentation of each of the oligosaccharides depended 
varied between the individual microbial communities (Figures S2 and S3). However, PCA 
plots based on samples from each of the communities (Figures 2 and 3) revealed a 
number of specific metabolites, which were typically seen to differ dependent of substrate 
(oligosaccharide) source (Tables 3 and 4). Typically, we observed that BA and LA 
metabolite profiles were similar to each other, but different from the profiles measured after 
fermentation of HA or FOS. 
Metabolites which increased after fermentation with AOS included phenylalanine, 
xanthine, linoleic acid or its derivatives. A possible source of phenylalanine was bacterial 
degradation of arabionofuranosyl structures, present in the AOS [11]. Arabionofuranosyl 
structures were partly causing the observed difference between HA and LA or BA, 
respectively. The HA fermentation fraction, which was enriched for high- mass 
carbohydrates, was also higher in feruloylated AOS (Table 4). It has previously been 
suggested that non-digestible carbohydrates with low mass reach the proximal colon, 
while non-digestible carbohydrates with higher mass travel all the way to the distal colon 
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[31]. Therefore, ingestion of HA and LA fractions may result in alterations in different parts 
of the bowel. Additionally, increased amounts of feruloylated AOS in the HA fraction may 
lead to a higher probability of the non-digestible carbohydrate to reach the distal colon, 
and prevent the accumulation of toxic by-products of proteolysis and amino acid 
fermentation, which takes place mainly when carbohydrates are absent [32,33]. 
Decomposition of the feruloylated AOS by the intestinal microbiota might lead to an 
increase in the amount of phenylalanine available for epithelial cells. This essential amino 
acid is a precursor for tyrosine, signaling molecules such as dopamine, noradrenaline and 
adrenaline as well as skin pigment – melanin [20,34].  
A flavonoid released during fermentation was mostly correlated to HA and FOS in the PCA 
plots (Figure 3). However, a significant increase was observed for all of the tested 
carbohydrates (Figure 4). Flavonoids may be released by microbial fermentation of plant 
structures present in the fecal matter. Flavonoids are shown to have various biological 
effects on the human body. Researchers have a key interest in the antioxidative 
ramification of those polyphenolic compounds against cancer, atherosclerosis and chronic 
inflammation [35,36], as they are known to inhibit and induce a large number of 
mammalian enzymes [37] involved in e.g. cell division, proliferation and detoxycation [38]. 
Absorption of flavonoids from the diet was long considered to be negligible, as they are 
present in foods bound to sugars as β-glycosides [39]. It has now been shown that the 
final biological activity of flavonoids depends on the intestinal bacterial metabolism, which 
breaks the β-glycosidic bondsand leads to biotransformation of some flavonoic 
compounds, thereby changing their bioactivity [40]. Many Lactic Acid Bacteria (LAB)are 
able to brake the β-glycosidic bonds, and the observed increase in the number of 
Bifidobacteria may have caused a higher amount of free flavonoids to be released, as 
observed in the HA fraction and FOS. Xanthine, hypoxanthine and allantoic acid are all 
products of purine metabolism [34]. Fermentations with all of the tested oligosaccharides 
(Figure 4, No. 9, 18, 22) showed a significant increase in the abundance of these 
metabolites, indicating an activation in this pathway compared to the NC incubations. 
Linoleic acid belongs to the group of essential unsaturated fatty acids, which humans are 
not able to synthesize. One of the health promoting properties of bifidobacteria is 
production of bioactive acids, namely the conjugated linoleic acid (CLA) [41], which is 
produced from linoleic acid available in the GIT, originating e.g. from consumed plant 
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tissues. Fermentations with non-digestable carbohydrates is known to cause an increase 
in CLA production. In this study, a positive correlation between the linoleic acid (No. 21) 
and bifidobacteria (Bis), was found (Figure 5). 
The metabolite production resulting from fermentation of HA was seen to differ from that 
resulting from fermentation of either LA or BA (Figures 2 and 3). The HA fraction had a 
greater impact on the production of 3-oxoalanine, tyramine and homoveratic acid. 3-
oxoalanine is found as an oxidation product of cysteine or serine containing substrates in anaerobic 
conditions [42,43]. In relation to the cysteine, mostly present in the fermentations with LA 
and BA (Figure  2, No. 6), this could possibly be an evidence of different sulfate containing 
amino acids metabolism in the high-mass fraction, in relation to the pathway or turnover 
speed. Consumption of tyramine, which is produced mainly by lactic acid bacteria (LAB), is 
reported to cause allergies, migraine and heart failure in very high concentrations [44,45]. 
However, this is in relation to the dietary products already high in the concentration of 
tyramine and not the production of this essential monoamine by intestinal bacteria, in case 
of which many co-metabolic relations are still highly unstudied. Homoveratic acid is a 
metabolite found in urine samples [46,47], plant cells [48] and microbial cells [49]. Both, 
homoveratic acid and tyramine may have an effect on eukaryotic endocrine metabolic 
pathways. Fermentation of AOS, and particularly the HA fraction, was seen to increase the 
abundance of these metabolites. However, considering the phenolic structure of 
homoveratric acid and tyramine, it could also be a product of bacterial degradation of 
ferulic structures present in the AOS fractions.                      
The HA fraction also had some part of the metabolic response in common with FOS, as 
N’-acetylspermidine and phenyllactic acid were increased typically in HA as well as FOS 
fermentations. N’-acetylspermidine have substantial and fundamental roles in various 
biological systems including mammals, plants and microbes [20]. Whether bacterial N’-
acetylspermidines affect epithelial cell growth and proliferation remains to be addressed. 
Phenyllactic produced by LAB, has been shown to prevent growth of pathogens [50,51]. 
Figure 5 suggests that the abundance of phenyllactic acid is rather related to the presence 
of Lactobacillus than to Bifidobacterium, however the Lactobacillus populations did not 
increase during fermentations (Figure S1). While the metabolite profiles produced by BA 
and LA fermentation in all the individual microbiotas were different from those produced by 
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HA and FOS (Figures 2 and 3), no significant differences in the metabolic profiles were 
observed between the BA and LA fractions (Figures 2, 3 and 4). We speculate that 
intestinal bacteria were more prone to metabolize the carbohydrates with lower mass, 
which were present in rather high amounts in BA (Figure 1). Metabolites typically 
correlated with the BA and LA fractions were cysteine, aminobenzoic acid and 3-
oxooctadecanoic acid. Cysteine may arise from bacterial metabolism of plant structures 
[34], and it has been shown that free cysteine contributes to the maintenance of anaerobic 
conditions by binding free oxygen [52]. This may be important for human health by 
preventing formation of free radicals in the intestines. Cysteine is also known to increase 
the pH during fermentation by buffering the environment [53]. However, high pH in the 
intestine is not desired, and low pH is known to have anti-cancerogenic effect in the 
human colon [54,55]. High amounts of cysteine, may increase the pH in the fermentation 
cultures, and may explain the higher number of Desulfovibrio spp. observed in the BA and 
LA fermentations (Table 2), since this species may have a competitive advantage at high 
pH. Additionally, previous reports show that cysteine supports the growth of this 
Desulfovibrio [56]. Aminobenzoic acid could be originating from degradation of 
phytochemicals or ferulic structures (present in the AOS fractions) by the microbial 
communities [34]. It has previously been suggested that the intestinal microbiota 
transforms phenolic compounds into bioactive forms, which are anticipated to have a 
positive influence on the human health [57]. 3-Oxooctadecanoic acid (11, 17) and (R)-3-
hydroxy-octadecanoic acid (12) are building blocks of the unsaturated fatty acids [34]. 3-
Oxooctadecanoic acid (17) was seen to increase in all six microbiotas after fermentation of 
at least two of the AOS fractions, and also increased in four out of six microbiotas after 
FOS fermentation (Figure 4). Additionally, differences between abundance of fatty acid 
derivatives no. 14 and 20 suggest that AOS and FOS might have an impact on the 
unsaturated fatty acid metabolism carried out by the intestinal microbiota, but that different 
turnover rates and different pathways are used, [34], depending on the microbiota 
composition as well as on the type of oligosaccharide. 
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Table 2. Relative fold change of bacteria target in samples incubated with BA, LA, HA or FOS 
compared to the NC samples (set to 1) for each of the six fecal communities. 
  
Substrates 
 Community BA LA HA FOS 
B
ifi
do
ba
ct
er
ia
  
1 1.32 (±0.03)b 1.34 (±0.02) b 1.35 (±0.02) b 1.01 (±0.02)a 
2 1.71 (±0.05)a 1.67 (±0.03) a 1.75 (±0.02) a 1.63 (±0.10) a 
3 1.84 (±0.02)a 1.91 (±0.04) a 2.17 (±0.14) ab 2.46 (±0.04) b 
4 1.29 (±0.04)ab 1.34 (±0.03) b 1.35 (±0.05) b 1.16 (±0.03) a 
5 1.25 (±0.02) a 1.30 (±0.02) a 1.40 (±0.01) ab 1.56 (±0.02) b 
6 5.54 (±0.06) a 5.54 (±0.05) a 5.11 (±0.07) b 3.85 (±0.07) c 
C
. c
oc
co
id
es
 g
ro
up
 1 0.93 (±0.01) a 1.00 (±0.02) ab 1.14 (±0.05) b 1.09 (±0.06) ab 
2 0.60 (±0.01) b 0.25 (±0.06) c 0.64 (±0.01) ab 0.85 (±0.03) a 
3 0.21 (±0.02) ab 0.20 (±0.03) b 0.44 (±0.03) c 0.36 (±0.03) ac 
4 0.66 (±0.03) a 0.86 (±0.13) ab 0.62 (±0.16) a 1.20 (±0.01) b 
5 0.28 (±0.02) a 0.25 (±0.04) a 0.33 (±0.01) a 0.68 (±0.02) b 
6 0.46 (±0.01) a 0.33 (±0.09) a 0.49 (±0.04) a 0.98 (±0.04) b 
A
lis
tip
es
 s
pp
. 
1 0.97 (±0.02) a 0.91 (±0.02) a 0.77 (±0.03) b 0.77 (±0.01) b 
2 0.79 (±0.05) a 0.60 (±0.06) a 0.80 (±0.08) a 0.67 (0.07) a 
3 0.73 (±0.01) a 0.72 (±0.01) a 0.82 (±0.06) a 0.79 (±0.07) a 
4 0.70 (±0.01) a,b 0.76 (±0.04) a 0.62 (±0.03) b 0.78 (±0.01) a 
5 0.58 (±0.02) a 0.55 (±0.05) a 0.59 (±0.03) a 0.51 (±0.01) a 
6 1.01 (±0.02) a 0.86 (±0.06) b 0.99 (±0.03) a,b 0.71 (±0.02) c 
D
es
ul
fo
vi
br
io
 s
pp
. 1 0.95 (±0.04) 
a 0.81 (±0.03) a 0.50 (±0.07) a 0.78 (±0.19) a 
2 0.90 (±0.02) a 0.88 (±0.02) a 0.55 (±0.03) b 0.69 (±0.01) b 
3 0.76 (±0.01) a,c 0.87 (±0.02) a 0.50 (±0.05) b 0.62 (±0.09) b,c 
4 0.79 (±0.01) a 0.82 (±0.02) a 0.68 (±0.04) a 0.70 (±0.02) a 
5 0.67 (±0.02) a 0.64 (±0.04) a 0.67 (±0.04) a 0.56 (±0.08) a 
6 0.84 (±0.01) a 0.69 (±0.13) a 0.78 (±0.08) a 0.94 (±0.06) a 
All calculated data are means ± SEM of triplicate fermentations. Results in the same row followed 
by different roman letters a-c indicate significant difference in bacterial abundance between the 
four substrates. Italic indicates no significant difference from NC sample (P>0.05). 
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Figure 1 Size exclusion chromatography of mixed arabino-oligosaccharides (MA), low mass 
arabino-oligosaccharides (LA), and high mass arabino-oligosaccharides (HA) in comparison with 
arabinose and 1.3 kDa pullanan standard. 
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Figure 2 PCA bi-plots (scores and loadings present on the same plot) of the fermentation 
samples with different arabino-oligosaccharides BA, LA and HA; and well known prebiotic FOS. 
Data from LCMS analyses in positive mode for tested bacterial floras separately (B1 – B6). 
Phenylalanine (1) was observed on the border of the 1 min and 2 min bucket, which is why PCA 
plots are showing metabolite no. 1 twice. LCMS chromatogram studies (data not shown) confirmed 
that it was indeed the same metabolite.  
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Figure 3 PCA bi-plots (scores and loadings present on the same plot) of the fermentation 
samples with different arabino-oligosaccharides BA, LA and HA; and well known prebiotic FOS. 
Data from LCMS analyses in negative mode for tested bacterial floras separately (B1 – B6).   
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Figure 4 Heat maps based on the LCMS data of selected metabolites from fermentation 
samples with BA, LA and HA, and FOS Fermentations in bacterial communities derived from six 
different individuals (B1-B6) are presented separately (B1-B6). M.No. designates metabolite 
numbers given in Tables 4 and 5. Red color indicates P-value < 0.005 and yellow color 0.005 < P-
value < 0.05 for differences between metabolite abundance before and after fermentation. Only 
metabolites that increased during fermentation are included. White color indicates a P-value > 0.05 
or a change ratio ≤ 1. Metabolites above the black line were found in positive mode, while those 
below the line were found in negative mode. 
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Figure 5  PCA loading plot of selected metabolites (numbers corresponding to Tabels 3 and 4) 
combined with microbial abundance data (abbreviations corresponding to Table1).  
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Supplementary tables and figures 
Table S1    16S rRNA gene sequences of bacterial taxonomic units. 
Target taxon Primer No. Sequence (5’-3’) Fragment size (bp) Reference 
Firmicutes phylum# 
Firm934F 1 gga gya tgt ggt tta att cga agc a 
126 [58] 
Firm1060R  agc tga cga caa cca tgc ac 
Clostridium 
coccoides group 
g-Ccoc-F 2 aaa tga cgg tac ctg act aa 
440 [59] 
g-Ccoc-R  ctt tga gtt tca ttc ttg cga a 
Clostridium leptum 
subgroup 
Clep866mF 3 tta aca caa taa gtw atc cac ctg g 
314 [60] 
Clept1240mR  acc ttc ctc cgt ttt gtc aac  
Roseburia spp. 
RosF 4 tac tgc att gga aac tgt cg  
230 [61] 
RosR  cgg cac cga aga gca at 
Lactobacillus spp. 
Lacto-F 5 agc agt agg gaa tct tcc a 
341 [62,63] 
Lacto-R  cac cgc tac aca tgg ag 
Bacteroidetes 
phylum 
Bact934F 6 gga rca tgt ggt tta att cga tga t 
126 [58] 
Bact1060R  agc tga cga caa cca tgc ag 
Bacteroides spp. 
BacF 7 cga tgg ata ggg gtt ctg aga gga 
238 Unpublished 
BacR  gct ggc acg gag tta gcc ga 
Bacteroides fragilis 
group 
Bfr-F 8 ctg aac cag cca agt agc g 
230 [64] 
Bfr-R  ccg caa act ttc aca act gac tta 
Prevotella spp. 
PrevF 9 cac caa ggc gac gat ca 
283 [61] 
PrevR  gga taa cgc cyg gac ct 
Alistipes spp. 
Alis F1-124 10 tta gag atg ggc atg cgt tgt 
320 [65] 
Alis R1-423  tga atc ctc cgt att acc gcg 
Bifidobacterium spp. 
F-bifido 11 cgc gtc ygg tgt gaa ag 
244 [66] 
R-bifido  ccc cac atc cag cat cca 
Akkermansia 
muciniphila 
AM1 12 cag cac gtg aag gtg ggg ac 
327 [67] 
AM2  cct tgc ggt tgg ctt cag at 
Enterobacteriaceae 
Eco1457F 13 cat tga cgt tac ccg cag aag aag c  
195 [68] 
Eco1652R  ctc tac gag act caa gct tg 
Desulfovibrio spp. 
DSV691-F 14 ccg tag ata tct gga gga aca tca g 
136 [69] 
DSV826-R  aca tct agc atc cat cgt tta cag c 
V2-V3 16S rRNA  
region* 
HDA1 15 act cct acg gga ggc agc agt 
200 [63] 
HDA2  gta tta ccg cgg ctg ctg gca c 
*The HDA primer was used as total bacteria DNA targets in order to normalize, hence correcting differences in total DNA 
concentration between individual samples.#The primer targets the 16S rRNA gene sequence of the Firmicutes phylum 
and the Bifidobacterium group. 
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Bacteroidetes phylum
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Bifidobacterium spp.
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Figure S1 (3 pages)  Relative quantity of the bacterial taxa in samples incubated with either 
BA, LA, HA, FOS or no carbon-source added (NC samples) for each of the six fecal communities. 
The horizontal lines show the mean of the six observations. Asterisks indicate significant 
differences from the NC samples (P<0.05 (*), P<0.01 (**), P<0.001 (***)).  
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Figure S2 PCA score plot of the fermentation samples with the different arabino-
oligosaccharides BA, LA and HA; and the established prebiotic FOS. Data originate from LCMS 
analysis in positive mode for all tested bacterial floras (B1 – B6). 
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Figure S3 PCA score plot of the fermentation samples with the different arabino-
oligosaccharides BA, LA and HA and the established prebiotic FOS. Data originate from LCMS 
analysis in negative mode for all tested bacterial floras (B1 – B6). 
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Abstract 
We compared fecal microbial communities derived either from Ulcerative Colitis (UC) 
patients in remission (n=4) or in relapse (n=4), or from healthy subjects (n=4).  These 
communities were used for inoculation of a dynamic in vitro gut model (M-SHIME), 
adapted from the validated Simulator of the Human Intestinal Microbial Ecosystem 
(SHIME) by incorporation of mucin-covered microcosms. Denaturing Gradient Gel 
Electrophoresis (DGGE) and quantitative PCR (qPCR) were applied for analysis of the 
‘luminal’ and ‘mucosal’ microbiota after 42 hours colonization in the model. Liquid 
Chromatography coupled with Mass Spectrometry (LCMS) was used for analysis of 
metabolites in the luminal and mucosal samples.  
Dice-based cluster analysis of PCR-DGGE fingerprints as well as Principal Component 
Analysis (PCA) of qPCR data revealed that the microbiota of the ‘mucus’ largely differed 
from that of the ‘lumen’. This was due to decreased mucus-associated populations of lactic 
acid producing bacterial populations (LAB) and increased mucus-associated populations 
of Roseburia spp. Importantly, qPCR revealed that LAB originating from UC patients had a 
significantly decreased capacity to colonize the mucin-covered microcosms as compared 
to those originating from healthy subjects.  
LCMS data indicated that bacterial communities derived from healthy subjects and UC 
patients in relapse differed with respect to metabolism of phenylalanine, tryptophan, and 
secondary bile acids. We found significant differences between the metabolomes of UC 
patients in relapse and remission, respectively, while the metabolome of patients in 
remission resembled that of healthy subjects.  
These novel findings constitute an important contribution to the understanding of the 
complex etiology of UC. 
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Introduction  
The mucus layer lining the epithelium of the gastrointestinal tract is important for the 
protection of the intestinal epithelium in humans. Commensal bacteria have been found to 
colonize the colonic mucus layer, and previous studies have shown that the microbial 
community found in the colonic mucus differs from that of the luminal community (Eckburg 
et al, 2005; Zoetendal et al, 2002). Several microbial characteristics have contributed to 
the evolvement of the specifically selected mucosal community, including the ability of the 
bacteria to utilize mucin glycans as energy source as well as resistance to nonspecific 
antimicrobial peptides and specific antimicrobial immunoglobulins produced by the host 
(Johansson et al, 2008; Killer &.Marounek, 2011). Additionally, many adhesion molecules 
expressed by colonic bacteria have mucin glycans as specific epitopes (Kline et al, 2009; 
Pretzer et al, 2005), and it has been suggested that the glycosylation pattern in mucin, 
hence the attachment site and energy source for the colonic bacteria, is an important 
factor for host selection of a specific mucosal community (Johansson et al, 2008). Lack or 
defects in the mucosal barrier may allow bacteria to reach the epithelium and trigger 
colonic inflammation.  
 Ulcerative colitis (UC) is an idiopathic inflammatory bowel disease characterized by 
chronic relapsing inflammation of the colonic mucosa (Ardizzone, 2003; Kornbluth 
&.Sachar, 2010). The etiology of UC remains an enigma, and no known infectious agent 
has been demonstrated (Loftus, 2004; Sartor, 2006). It has been speculated that UC 
originates from a dysregulated immune response to the commensal intestinal microbiota in 
genetically susceptible individuals (Brown &.Mayer, 2007; Hanauer, 2006). Human studies 
have revealed that UC patients have a colonic mucus layer that has an altered O-glycan 
profile and is significantly thinner than that of healthy subjects, which may select for a 
different mucosal microbial profile (Larsson et al, 2011; Pullan et al, 1994). Consistently, 
several studies have shown that patients with UC have an altered bacterial microbiota 
(Frank et al, 2007;Qin et al, 2010;Sokol et al, 2009;Takaishi et al, 2008). Thus, the 
bacterial and/or host-bacterial interactions may play a role in the pathogenesis of UC.  
In vitro models are well-suited to screen the adhering potency of intestinal microbes. They 
include adhesion assays to various components of the intestinal surface: e.g. intestinal 
mucus (Ouwehand et al, 2002b), mucins (Van den Abbeele et al, 2009), colonic tissue 
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(Ouwehand et al, 2002a) or cell lines (Laparra &.Sanz, 2009). A drawback to such models 
is that they often provide only short-term information based on axenic cultures and thus 
ignore the interactions between and within the luminal and mucosal microbial 
communities. Therefore, a dynamic in vitro gut model has been developed, which 
simulates both the luminal and mucosal environment (Van den Abbeele et al, 2011a). This 
model, named the M-SHIME was adapted from the validated Simulator of the Human 
Intestinal Microbial Ecosystem (SHIME) (Van den Abbeele et al, 2010). Compared to 
earlier in vitro models, the M-SHIME allows a more representative colonization of specific 
Lactobacillus sp (Van den Abbeele et al, 2011a). Furthermore, high-resolution 
phylogenetic microbiota profiling shows that the simulated mucosal microbiota is, in 
correspondence with in vivo studies, enriched with Firmicutes belonging to the Clostridial 
clusters IV and XIVa (Van den Abbeele et al, 2010). Moreover, the in vitro mucosal 
environment is necessary to avoid the wash-out of specific surface-associated microbes, 
which occurs in conventional in vitro models. Hence, the M-SHIME allows studies of the 
mucosal microbiota and the interaction between luminal and mucosal microbial 
communities.     
The aims of this study were (1) to investigate the ability of fecal microbiota from healthy 
subjects and UC patients in either remission or relapse to colonize the artificial mucus 
layer of the M-SHIME and (2) to elucidate microbial activity by comparison of metabolic 
profiles of the luminal and mucosal microbial communities derived from UC patients and 
healthy subjects. Denaturing Gradient Gel Electrophoresis (DGGE) and quantitative Real-
Time PCR (qPCR), both of which are culture-independent methods, were applied for 
microbiota analysis, while LCMS was used to analyze the potential role of extracellular 
metabolites produced by microorganisms in the lumen and mucus of the M-SHIME.  
 
Materials and Methods 
Human volunteers and clinical characteristics of UC patients 
Fecal samples were obtained from 8 patients with UC and 4 healthy controls (Langholz et 
al, 1994). Within the UC group, 4 patients were in clinical remission and 4 patients had 
active disease at the time of sampling according to clinical and endoscopical criteria 
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(Binder, 1970). The study was performed in accordance with the Second Helsinki 
Declaration, reported to the Danish Data Protection Agency and approved by the Regional 
Ethics Committee. Written informed consent was obtained from each participant under a 
protocol approved by the Danish National Committee on Biomedical Research Ethics. All 
four patients with active UC were treated with mesalazine (5-aminosalicylic acid). Two 
patients with inactive UC received mesalazine, one patient received olsalazine (6-
hydroxybenzoate)-salicylic acid), and one received no immunosupressive treatment. None 
of the participants had been treated with antibiotics for at least 2 months before enrolment 
and there was no significant difference (P = 0.32) in the mean age of the participants when 
comparing the 3 groups. 
 
Sample collection and processing 
Stool samples were collected in airtight containers and stored at 4°C (limited storage time 
was encouraged (Ott et al, 2004)) until delivery to the laboratory. Feces were 
homogenized in glycerol to give a 25% feces/glycerol slurry. This was performed in an 
anaerobic cabinet (Macs Work Station, Don Whitley, containing 10% H2, 10% CO2, and 
80% N2). The processed samples were stored at -80°C until further analysis. 
 
Growth medium and chemicals 
Unless stated otherwise, chemicals were obtained from Sigma (Bornem, Belgium). The M-
SHIME feed contained 1.0 g/l arabinogalactan, 2.0 g/l pectin, 1.0 g/l xylan, 3.0 g/l starch, 
0.4 g/l glucose, 3.0 g/l yeast extract, 1.0 g/l peptone, 4.0 g/l mucin, and 0.5 g/l cystein. 
Pancreatic juice contained 12.5 g/l NaHCO3, 6.0 g/l bile salts (Difco, Bierbeek, Belgium) 
and 0.9 g/l pancreatin. Mucin agar was prepared by boiling autoclaved distilled H2O 
containing 5% porcine mucin type II and 1% agar. The pH was adjusted to 6.8 with 10 M 
NaOH. 
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M-SHIME 
Analysis in the M-SHIME dynamic gut model was carried out as previously described 
(Vermeiren et al, 2012) at two different occasions with six participants for each 42-hours 
run (two healthy, two UC patients in remission and two UC patients in relapse). The 
position (vessel) of the inocula from either healthy subjects or UC patients was changed 
for each run.  
 
Microbial activity in terms of short-chain fatty acids (SCFA) 
Acetate, propionate, butyrate, valerate, caproate and branched SCFA (isobutyrate, 
isovalerate and isocaproate) were measured as described previously (De Weirdt et al, 
2010). 
 
Extraction of bacterial DNA 
Before extraction of the mucosal samples, the samples were heated for 15 min at 55oC to 
make the agar soluble. Subsequently, DNA was extracted from thawed samples using the 
QIAamp DNA Stool mini kit (Qiagen, Hilden, Germany) with a bead beater step in 
advance, as previously described (Leser et al, 2000). For each sample, DNA was 
extracted in duplicates. The purified DNA was stored at -20°C until use. 
 
PCR amplification for DGGE 
Aliquots (10 μL) of purified DNA (5 ng/µl of pooled DNA from the duplicate DNA 
extractions) were applied to the following to give a 50 μL PCR reaction mixture: 20 μL of 5 
PRIME MasterMix (2.5×) (VWR & Bie & Berntsen) and 10 pmol of each of the primers 
(Eurofins MWG Synthesis GmbH, Ebersberg, Germany). Primers HDA1-GC/HDA2 (Walter 
et al, 2000) targeting 16S rRNA genes from all bacteria were used in a touchdown PCR as 
previously described (Petersen et al, 2010) 
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Analysis of luminal and mucosal microbiota by DGGE 
DGGE was carried out as described previously (Bernbom et al, 2006) using a DcodeTM 
Universal Mutation Detection System instrument and gradient former model 475 according 
to the manufacturer’s instructions (Bio-Rad Labs, Hercules, California). The 9% polyamide 
gels were made with denaturing gradients ranging from 25% to 65%. The 100% 
denaturant solution contained 40% formamide and 7M urea. Thirteen microlitres PCR 
products were mixed with 3 µL loading dye before loading. Gels were run in 1 x TAE at 60 
°C for 16 h at 36 V, 28 mA, stained with ethidium bromide for 15 min, destained for 20 min, 
and viewed by UV-B trans illumination at 302 nm (Bio-Rad). The BioNumerics software, 
version 4.60 (Applied Maths, Sint-Martens-Latem, Belgium) was used for identification of 
bands and normalization of band patterns from DGGE gels. DGGE gels were normalized 
by an assigned marker (developed in our laboratory). A cluster analysis was performed 
based on Dice coefficient of similarity (weighted) using the unweighted pair group method 
and the arithmetic averages clustering algorithm. 
 
Quantitative PCR assay conditions 
QPCR was performed on an ABI Prism 7900 HT from Applied Biosystems. The 
amplification reactions were carried out in a total volume of 11 μL containing; 5.50 μL 
(SYBR® Green, Applied Biosystems), primers (each at 200 nM concentration) (Eurofins 
MWG Synthesis GmbH), 2 μL template DNA, and Nuclease-free water (Qiagen) purified 
for PCR. The amplification was carried out as previously described (Vigsnaes et al, 2011). 
DNA (5 ng/µl) from the duplicate DNA extractions of each sample was used for the qPCR. 
 
Quantitative PCR primer and data handling 
The primers specific to regions of the 16S rRNA genes of 20 selected bacterial taxa are 
listed in Table S1 (supplementary data). The relative quantities of gene targets encoding 
gene sequences of the bacterial taxa were calculated using 2DeltaCt, assuming primer 
efficiency at 1.0. Delta Ct is the Ct-values of the bacterial target normalized against Ct-
values of the total bacterial population in a sample. Ct is the threshold cycle calculated by 
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the ABI software (SDS version 2.2; Applied Biosystems, Foster City, California, USA) as 
the PCR cycle, where amplification signal exceeds the selected threshold value, also set 
by the ABI software. Prior to the quantification, standard curves were created using serial 
10-fold dilutions of bacterial DNA extracted from one of the M-SHIME samples for all 
primer sets. Analysis of the standard curves allowed verification of PCR efficiency for the 
chosen PCR conditions. All primers were tested to confirm sensitivity and specificity using 
DNA from pure bacterial species (Table S2, supplementary data). The detection limit was 
set to 0.001% of the quantity of the total bacteria. Bacterial targets that could not be 
detected or were below the detection limit were set to one half of the detection limit for 
further calculations.  
 
Metabolite detection & identification  
Luminal samples from the M-SHIME were thawed on ice and subsequently centrifuged at 
3000 g for 15 min at 4°C. Cold methanol (around -80°C) in a ratio 1:1 was added to the 
supernatant. Metabolites from the mucosal samples, due to the semi-solid form, were 
extracted with 2 ml of cold 50% methanol and centrifuged at 3000g for 15 min at 4°C. This 
procedure was repeated twice. All of the samples were stored at -80°C until further 
analysis and centrifuged at 15000g for 5 min at 4°C just before LCMS analysis. The 
analysis of metabolites was conducted as follow: a Dionex Ultimate 3000 RS liquid 
chromatigraph (Dionex, Germering, Germany) coupled to a Bruker maXis time of flight 
mass spectrometer equipped with an electrospray interphase (Bruker Daltonics, Bremen, 
Germany). Analytes were separated on Kinetex pentafluorophenyl column 50 x 2.10 mm, 
2.6 µm, 100Å (Phenomenex, USA), using the solvent system: A, 10 mM ammonium 
formate pH 3.5, and B, acetonitrile. Solvent programming was isocratic 0% B to 0 min 
followed by a linear gradient to 100% B at 7 min and 100% B at 8 min. Flow rate was 0.25 
ml/min at 0 min, increased to 0.4 ml/min at 7 min. Solvent composition and flow were 
returned to initial conditions at 8.2 min. The oven temperature was 40°C. Injection volumes 
were 1 µl. The following electrospray interphase settings were used: nebulizer pressure 2 
bar, drying gas 10 l/min, 200°C, capillary voltage 4000V. Scan range was from 50 to 800 
m/z. The main focus of this study was acids, thus samples were analyzed in negative 
mode.  
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To identify metabolites seen to separate given groups, the Human Metabolome Database 
(HMDB; Wishart et al. 2009) was used. Molecular formulas of the metabolites from the 
LCMS analysis were generated based on exact mass and isotopic pattern with Bruker 
Daltonics Software. Identification of metabolites was based on a very low measurement 
error (Tab.1, Tab.2; external & internal calibration and lock mass was used), compared to 
the data given in HMDB and further references to the microbial metabolism in the GI. In 
addition hydrophobic properties of the molecule, indicated by the retention time in the 
chromatograph, were taken into consideration.  
 
Statistical analysis 
Statistical analysis of the qPCR data was performed using OriginPro software (version 8.1; 
OriginLab Corporation, Northampton, USA). Normality and homogeneity of variances of 
the qPCR data were assessed using the Kolmogorov-Smirnov and the Levene’s test, 
respectively. Log-transformations were performed for data that did not meet these criteria.  
T-testing was apllied to identify significant differences in colonization ability using the ratio 
(proportion) of the given bacterial taxon present in the two communities (lumen and 
mucus) for the three groups (healthy, UC patients in remission and UC patients in 
relapse). Univariate ANOVA was used to determine significant differences between 
specific bacterial taxa comparing the three groups either from lumen or mucus. Where 
ANOVA indicated a significant difference, Fisher’s least significant different test was used. 
The nonparametric Kruskal-Wallis test was used for datasets, which did not have 
homogeneity of variance or were not normally distributed even after log-transformation. 
Univariate ANOVA was applied to confirm that there was no age differences between the 
three disease groups. Tests were considered statistically significant if P-values lower than 
0.05 were obtained. Principal Component Analysis (PCA) of qPCR data was carried out 
using LatentiX® data analytical software (version 2.00, The Mathworks Inc., Copenhagen, 
Denmark). Differences in metabolite profiles were evaluated by PCA using Profile Analysis 
2.0 by Bruker Daltonics. Data was grouped into buckets of 1 min and 1 m/z differences in 
the range from 0.5 to 9 min and 50 to 800 m/z and normalized by the sum of buckets in the 
analysis. P-values were calculated by univariate ANOVA (α = 0.05) using the normalized 
values from the PCA. As for the qPCR analysis, tests were considered significant when P-
values lower that 0.05 were obtained. 
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Results 
Microbial activity in terms of SCFA production 
SCFA were analyzed in the luminal content of the colonic M-SHIME vessels as a measure 
of the metabolic activity of the microbiota derived from healthy subjects or UC patients, 
either in remission or relapse (Table 1). Forty-two hours after inoculation with fecal 
samples, there was a significant inter-individual variability within each group regarding the 
conversion of the provided nutrients to SCFA (P<0.05). As a result of this variability, no 
significant differences were detectable between the three groups. However, there was a 
trend of lower acetate and higher branched SCFA concentrations for UC patients as 
opposed to healthy subjects (P=0.138 and P=0.210, respectively).  Additionally, we found 
it noteworthy that the levels of carproate found in samples containing microbiota from 
patients in remission was 36 fold higher than in samples with microbiota from patients in 
remission (P=0.229). 
 
Microbial community analysis using DGGE 
Comparison of DGGE profiles containing 16S ribosomal genes amplified from luminal and 
mucosal samples of healthy subjects and UC patients after 42h colonization revealed a 
distinct difference between the dominant bacterial members of the luminal and mucosal 
environment (Figure 1). The dendrogram from the Dice cluster analysis showed three 
clusters with five luminal samples in cluster I (53.89% similarity), all mucosal samples in 
cluster II (54.61% similarity) and seven luminal samples in cluster III (41.15% similarity). 
Clustering of the distribution of these dominant microbial species did not correlate to the 
health status of the human subjects (healthy, UC in remission and UC in relapse). 
 
Microbial community analysis by qPCR 
For microbiotas derived from UC patients in relapse or remission, luminal and mucosal 
samples were clearly separated from one another, while this separation was not equally 
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clear for samples from healthy subjects (Figure 2, score plot). Especially the second 
principal component (PC2) explained the difference between the luminal and mucosal 
environments with Roseburia, Faecalibacterium prautznitzii, and 
Closteridiaceae/Eubacterium representing the mucosal environment and B. bifidum, B. 
adolescentis, Bifidobacterium spp., Lactobacillus spp., Akk. muciniphila and Actinobacteria 
representing  the luminal content (Figure 2, loading plot). 
It was noteworthy that the preference of specific bacterial groups to colonize the mucosal 
and/or luminal compartment was clearly affected by the origin of the microbiota (healthy 
subjects, UC patients in remission or UC patients in relapse) (Table 2). No significant 
differences between the luminal and mucosal samples with respect to proportions of 
specific bacterial taxa were measured when fecal communities were derived from healthy 
subjects. However, in the vessels with communities derived from UC patients in relapse, 
mucus was colonized by significantly lower proportions of bifidobacteria, B. bifidum, 
lactobacilli, C. coccoides group, C. leptum subgroup and Alistipes spp.(P=0.01, P=0.02, 
P=0.03, P=0.05, P=0.02, and P=0.05, respectively) than found in lumen. Additionally, the 
densities of bifidobacteria, B. adolescentis, B. pseudocatenulatum, lactobacilli, C. leptum 
subgroup, Faecalibacterium prausnitzii and Actinobacteria derived from UC patients in 
remission were significantly lower in mucus than in lumen (P=0.01, P=0.001, P=0.01, 
P=0.007 and P=0.05, P=0.03 and P=0.001, respectively). Finally, significantly higher 
mucosal counts of Roseburia spp. derived from UC patients in remission were measured 
(P=0.05) 
 Comparison  of the proportions of specific taxa present in the luminal and mucosal 
compartments, respectively, from the three types of microbiota (healthy, UC remission, UC 
relapse) revealed that relative quantities of Bifidobacterium spp. and Lactobacillus spp. in 
mucus was significantly lower (P=0.05 and P=0.002, respectively) in communities derived 
from UC patients in relapse than in those derived from healthy subjects, whereas the 
relative quantity of Clostridiaceae/Eubacterium was significantly higher in the lumen 
(P=0.04) in communities from UC patients in relapse than in those from healthy subjects 
(Table 3).  
The bacterial growth rate of selected bacterial taxa in the lumen was calculated from the 
slope of the exponential phase of the growth curves. The growth rate was increased during 
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the 42 h incubation in the lumen for all the examined bacterial taxa. No significant 
difference in the growth rate for each bacterial taxon was found when comparing the three 
groups (healthy subjects, UC in remission or UC in relapse) (Table S3, supplementary 
data).               
 
Metabolite detection and separation 
PCA of the metabolites as detected by LCMS revealed a difference between samples 
taken from healthy subjects and UC patients in relapse, respectively. The grouping was 
present in samples from mucus (Figure 3, score plot) as well as from lumen (Figure 4, 
score plot). No difference was observed between UC patients in remission and healthy 
subjects (Figure S1 and S2, supplementary data). However, a clear separation between 
score plots for UC patients in relapse and remission, respectively, was seen (Figure S3 
and S4, supplementary data).  
Based on the PCA loading plots (Figure 3 and 4), metabolites, which were tentatively 
causative for the difference observed between UC patients in relapse and healthy 
subjects, were identified (Table 4 and 5). Loadings, which in extracted ion chromatograms 
showed clear chromatogram peaks (data not shown) that were present in significantly 
different levels (P<0.05) in the two groups were further investigated. Substances in the 
Human Metabolome Database, which corresponded to the found mass/charge ratio 
(MLCMS) were identified. However, a few of the given mass/charge values had more than 
one possible match (Table 4 and 5).  
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Discussion 
In this study, we applied a recently developed dynamic in vitro gut model, the M-SHIME, to 
investigate differences between the intestinal microbial ecosystems of healthy subjects 
and UC patients, either in relapse or in remission. This model allows investigation of 
differences within the luminal content as well as at the artificial intestinal mucosal surface 
(Van den Abbeele et al, 2011a; Van den Abbeele et al, 2010). The impact of the human 
host on the microbial composition is eliminated, thus allowing focus on intrinsic features of 
the gut microbial populations.  
In line with recent in vivo (Hong et al, 2011; Nava et al, 2011) and in vitro studies (Van den 
Abbeele et al, 2012; Vermeiren et al, 2012), we have demonstrated that also in the M-
SHIME model, the in vitro mucosal microbial community differs from the luminal one 
(Figure 1), with specific butyrate-producing bacteria (e.g. Roseburia spp.) being abundant 
members of the mucosal microbiota (Table 2 and Figure 2). The luminal and mucosal 
bacteria have previously been demonstrated to display different roles in the host, and it 
has been proposed that the mucosal microbiota is more involved in interaction with the 
epithelial and immune cells than the luminal microbiota, because it resides closer to the 
intestinal epithelial cells (Derrien et al, 2011; Van den Abbeele et al, 2011b). Hence, an 
altered mucosal microbial community may play an important role in dysregulated immune 
responses.  
For samples from UC patients a significantly lower proportion of lactobacilli and 
bifidobacteria residing in the mucus-microcosm than in the lumen was observed, while this 
was not the case for healthy microbiotas (Table 2). Notably, this was observed for UC 
patients in remission as well for those in relapse, indicating that the impaired ability of the 
lactic acid bacteria to adhere to mucus is present also when UC patients are free of severe 
symptoms.  However, when directly comparing ‘mucosal’ populations from M-SHIME 
colonized with microbiota from UC patients to those colonized with healthy microbiotas, 
only patients in relapse had a significantly lower amount of bifidobacteria and lactobacilli 
than found in the ‘healthy’ samples (Table 3). This could be due to the fact that microbiota 
from UC patients in relapse in general contained lower amounts of lactic acid bacteria than 
microbiota derived from either healthy people or UC patients in remission.  Species or 
strain specific mucus adhesion promoting proteins have been reported in several 
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bifidobacteria and lactobacilli (Gilad et al, 2011; Kankainen et al, 2009; Kleerebezem et al, 
2010; Pretzer et al, 2005; Pridmore et al, 2004; Van Tassell & Miller, 2011). The 
expression of adhesion molecules may be changed in the lactic acid producing bacteria 
derived from UC patients, hence their inability to colonize the mucus in vitro. However, we 
would expect that host-induced differences in bacterial gene expression profiles would no 
longer prevail after 42 hours in the gut model. Alternatively, an altered composition of the 
species of lactobacilli and bifidobacteria derived from UC patients may explain the 
decreased ability of these groups to adhere to the mucin-microcosms of the M-SHIME.  A 
third explanation may be that within a given species, the strains of lactic acid bacteria 
present in UC patients are less capable of adhesion to mucins than their counterparts 
present in healthy subjects, perhaps due to minor genetic differences in adhesion-relevant 
genes.  
Bifidobacteria and lactobacilli are believed to play important roles in promoting intestinal 
health (Chenoll et al, 2011; Collado et al, 2007; Fooks &.Gibson, 2002; Hoarau et al, 2006; 
Lee et al, 2011; Lee et al, 2003; Saulnier et al, 2011; Zeuthen et al, 2010). The observed 
depletion of bifidobacteria and lactobacilli in UC patients in relapse, which is in line with a 
number of previous reports (Macfarlane et al, 2004; Mylonaki et al, 2005; Vigsnaes et al, 
2012), is likely to have a consequence for colonic health. It is, however, not possible from 
the given data to conclude whether the impaired adhesion capacity of lactic acid bacteria 
derived from UC patients is part of the cause or part of the effect of the disease. It may be 
that the mucus layers in the intestines of the UC patients have selected for populations of 
lactic acid bacteria, which are less optimized to adhere to the ‘healthy’ mucin of the M-
SHIME.  
 
Also the ability of the butyrate-producing clostridial groups C. coccoides and C. leptum to 
colonize the mucin-covered microcosms of the M-SHIME was found to be lower in 
bacterial communities from UC patients than in those originating from healthy subjects 
(Table 2). This may be linked to the lower abundance of lactobacilli and bifidobacteria in 
the microcosms, since these species produce acetate and/or lactate, which is 
subsequently utilized by the given clostridial groups. In contrast to the C. coccoides group 
and the C. leptum subgroup, the buturate-producing Roseburia spp. in microbiotas 
originating from UC patients demonstrated a high presence mucin-microcosms (Table 2), 
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indicating that these species, which are known to be able to degrade complex 
carbohydrates (Flint et al, 2007), are not dependent on the presence of lactate and acetate 
as seen for their clostridial relatives.  Hence, the low abundance of the clostridial groups 
within the mucin-microcosms may create a free ecological niche allowing for excessive 
colonization of Roseburia spp. 
Metabolomic (LCMS) analysis revealed that the microbiotas from healthy subjects and 
from UC patients in remission displayed very similar metabolisms, while the metabolism of 
bacterial communities from UC patients in relapse was clearly different from these two 
groups (Figure 3, 4, S1, S2, S3 and S4). We found that metabolism of bile acids, 
tryptophan and phenylalanine were altered in luminal as well as mucosal samples derived 
from UC patients in relapse as compared to healthy subjects (Table 4 and 5). The 
presence of drugs and drug metabolites in samples from UC patients in relapse was 
expected, since all four patients received mesalazine (5-aminosalicylic acid).  
In the human body, most bile acids are actively reabsorbed from the ileum and returned to 
the liver. However, a small fraction of bile acids escape enterohepatic circulation and enter 
the colon where bacteria metabolize the bile acids primarily by deconjugation and 
oxidation of hydroxyl groups. Bile salt hydrolysis is carried out by a broad spectrum of 
intestinal bacteria (Jones et al, 2008; Ridlon et al, 2006). However, the specificity of 
hydroxysteroid dehydrogenase (HSDH) varies depending on bacterial species and may 
either be specific for the 3-, 7-, and/or 12-hydroxy groups of bile acids leading to different 
secondary bile acids. Specific HSDHs have primarily been detected in a number of 
Clostridium and Eubacterium species belonging to either cluster I, IV (C. leptum 
subgroup), XIVa (C. coccoides group) or XIb (Doerner et al, 1997; Ridlon et al, 2006). As 
we demonstrated significantly higher levels of Clostridiaceae/Eubacterium in the luminal 
samples from UC patients in relapse than in healthy subjects (Table 3), this could partly 
explain the observed enrichment of secondary bile acids. High levels of secondary bile 
acids such as deoxycholic acids (primarily produced by species belonging to 
Clostridiaceae) can be detrimental for colon health (Mcgarr et al, 2005).  
Phenylalanine was more abundant in mucosal samples from the M-SHIME colonized with 
microbiota from healthy subjects, than in those colonized with samples from UC patients 
(Table 4). Products of phenylalanine that are normally metabolized by intestinal bacteria 
undergo a variety of processes in the body, where they may be detoxified by either 
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glucuronide or sulphate conjugation in the gut mucosa and liver, or remain unabsorbed 
and voided in feces (Smith & Macfarlane, 1997). Production of phenolic compounds by  
proteolytic and peptidolytic activities of the intestinal bacteria has previously been 
associated with various diseases including cancer and UC (Smith &.Macfarlane, 1997). 
Previous studies have shown that species belonging to the genera Clostridium and 
Bacteroides have a high capacity to ferment phenylalanine to phenolic compounds such 
as phenylpropionate, phenylacetate and/or phenyllactate (Elsden et al, 1976; Smith 
&.Macfarlane, 1996). Here, we observed higher levels of clostridia in samples derived from 
UC patients than in samples from healthy subjects (Table 3). Hence, we speculate that the 
enrichment of products of phenylalanine metabolism in mucosal and luminal samples 
derived from UC patients in relapse could be a result of the higher abundance of these 
bacterial groups (Table 4 and 5).  
Also tryptophan levels were higher in samples from the M-SHIME colonized with 
microbiota from healthy subjects than when it was colonized with microbiota from UC 
patients in relapse (Table 4 and 5). In line with this, previous studies have revealed that 
after fermentation using inocula from healthy subjects, no products of tryptophan 
metabolism could be detected in the system (Smith &.Macfarlane, 1996; Smith 
&.Macfarlane, 1997).  
Finally, we observed that unsaturated fatty acids (FA) were significantly higher in mucus 
compartments colonized with bacteria from UC patients in relapse than in those colonized 
with ‘healthy’ bacterial communities (Table 4). Previous metabolomic research has 
revealed changes of FA in serum of UC patients (Hengstermann et al, 2008; M.Esteve, 
2004), and has suggested that these changes could be caused by increased endogenous 
biosynthesis of polyunsaturated fatty acids (PUFA) and by increased lipolysis initiated by 
cytokines during the inflammatory response. Based on the present work, we speculate that 
the altered levels of FA in serum UC patients in relapse compared to healthy subjects 
could be originating from the intestinal microbial metabolism.  
 
In conclusion, our data suggest that the significantly altered intestinal bacterial community 
present in UC patients in relapse results in a significantly altered bacterial metabolic 
profile. The observed bacterial alterations are suggested to result in increased metabolism 
of phenylalanine and tryptophan in microbial communities from UC patients in relapse. 
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While UC patients in remission display microbiotas and metabolomes very similar to those 
of healthy subjects, the lactic acid bacteria present in patients in remission are, similarly to 
those from the relapse samples, significantly impaired in their ability to adhere to the 
mucus microcosms of the M-SHIME. This may be due to a different composition or a 
different genetic makeup of the lactic acid bacteria present in all UC patients, which may 
play a role in the etiology of this disease.  We suggest that probiotic therapy for UC 
patients should not exclusively aim at increasing the amount of lactic acid bacteria present 
in the gut, which has previously proved helpful (Zocco et al, 2006), but also at replacing 
the existing lactic acid bacteria with other strains/isolates with better capacity for mucosal 
adhesion.   
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Tables and figures 
Table 1    The average (± SEM) absolute SCFA levels (mM) 
in the luminal content of the M-SHIME units, 42h after 
inoculation with fecal samples of different human subjects: 
healthy, UC remission and UC relapse (n = 4).  
 Healthy 
UC 
remission 
UC relapse 
Acetate 54.0 ± 3.8 40.7 ± 4.9 46.1 ± 6.0 
Propionate 7.3 ± 0.3 6.2 ± 3.2 9.4 ± 1.4 
Butyrate 23.6 ± 5.3 18.9 ± 4.2 23.8 ± 3.4 
Valerate 0.6 ± 0.6 1.6 ± 0.8 0.7 ± 0.6 
Caproate 1.5 ± 1.5 3.6 ± 2.8 0.1 ± 0.1 
Branched 
SCFA 
2.0 ± 1.6 5.1 ± 1.2 3.2 ± 1.3 
Total SCFA 89.1 ± 2.5 76.2 ± 4.6 83.3 ± 7.6 
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Table 4    Annotated metabolites, which differ between healthy subjects and UC patients in relapse 
(mucus) 
Enriched in UC relapse      
No. Metabolite candidate MPCA (Da)/ RT (min) MLCMS (Da) MHMDB (Da) 
Error 
(mDa) P values 
1 Monounsaturated fatty acids (C18) 281.5/6 281.248569 281.248627 0.058 P<0.05 
2 Polyunsaturated fatty acids (C18) 279.5/6 279.232812 279.232971 0.159 P<0.05 
3 Secondary bile acids 391.5/4 391.285401 391.285400 0.001 P<0.05 
4 Salicyluric acid (drug) 194.5/2 194.046042 194.045883 0.159 P<0.001 
5 Monounsaturated fatty acids (C18) 282.5/6 281.248569 281.248627 0.047 P<0.05 
6 
Aminosalicylic acid (drug 
metabolite) or 3-Hydroxyanthranilic 
acid (oxidation product of 
tryptophan metabolism) 
152.5/1 152.035358 152.035309 0.049 P<0.01 
7 Product of phenylalanine metabolism 149.5/3 149.060764 149.060806 0.042 P<0.01 
Enriched in healthy subjects      
No. Metabolite candidate MPCA (Da) MLCMS (Da) MHMDB (Da) 
Error 
(mDa) 
 P 
values 
8 Tryptophan 203.5/2 203.082491 203.082596 0.105 P<0.05 
9 Phenylalanin 164.5/1 164.071619 164.071701 0.082 P<0.005 
10 
Hydroxyphenyllactic acid or 3-(3-
hydroxyphenyl)-3-hydroxypropanoic 
acid 
181.5/2 181.050629 181.050629 0.531 P<0.05 
Numbers from 1-10 correspond to the metabolite marked in the loading plot Figure 3. MPCA 
designates mass taken from PCA; RT designates retention time bucket of the PCA; MLCMS 
designates mass taken from LCMS analysis of test samples; MHMDB designates mass given by 
Human Metabolome Data Base; ‘Error’ designates the mass difference between measured MLCMS 
and found MHMDB. 
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Table 5    Annotated metabolites, which differ between healthy subjects and UC patients in relapse 
(lumen) 
Enriched in UC relapse      
No. Metabolite candidate MPCA (Da)/ RT (min) MLCMS (Da) MHMDB (Da) 
Error 
(mDa) P values 
11 Secondary bile acids 391.5/4 391.285527 391.285400 0.127 P<0.01 
12 Salicyluric acid (drug) 194.5/2 194.046042 194.045993 0.110 P<0.001 
13 
Aminosalicylic acid (drug 
metabolite) or 3-Hydroxyanthranilic 
acid (oxidation product of 
tryptophan metabolism) 
152.5/1 152.035358 152.035309 0.052 P<0.05 
14 Product of phenylalanine metabolism 149.5/3 149.060764 149.060806 0.122 P<0.001 
Enriched in healthy subjects      
No. Metabolite candidate MPCA (Da) MLCMS (Da) MHMDB (Da) 
Error 
(mDa) 
 P 
values 
15 Tryptophan 203.5/2 203.082491 203.082596 0.278 P<0.001 
16 
Phenyllactic acid or 4-
methoxyphenylacetic acid  
or desaminotyrosine 
165.5/3 165.055687 165.055710 0.023 P<0.05 
17 Phenylglycine 150.5/2 150.056153 150.056046 0.107 P<0.001 
Numbers from 11-17 correspond to the metabolite marked in the loading plot Figure 4. MPCA 
designates mass taken from PCA; RT designates retention time bucket of the PCA; MLCMS 
designates mass taken from LCMS analysis of test samples; MHMDB designates mass given by 
Human Metabolome Data Base; ‘Error’ designates the mass difference between measured MLCMS 
and found MHMDB. 
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Figure 1 Dice cluster analysis of universal DGGE gel profiles from in vitro luminal and mucosal 
communities of the M-SHIME colonized with samples derived from healthy subjects,or from UC 
patients in remission or relapse. The luminal samples are indicated by stars (*) and the mucosal 
samples are indicated by full circle (•). The dendrogram can be divided into three clusters: Cluster 
I. luminal samples (53.89% similarity). Cluster II. mucosal samples (54.61% similarity). Cluster III. 
luminal samples (41.15% similarity). Metric scale indicates degree of similarity in percentages. 
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Figure 2 Principal Component Analysis of the quantitative PCR measurements illustrated by. 
PC1 and PC2 (29.9% and 21.3% of explained variance, respectively). Score plot showing the M-
SHIME luminal (Δ) and mucosal (о) communities. Sources of the communities are indicated by 
green for healthy subjects, blue for UC patients in remission and red for UC patients in relapse. 
Loading plot indicating each of the measured bacterial taxa as determined by quantitative Real-
Time PCR. 1. B. bifidum; 2. B. adolescentis; 3. B. pseudocatenulatum; 4. Bifidobacterium spp.; 5. 
Lactobacillus spp.; 6. C. leptum subgroup; 7. C. coccoides group; 8. F. prausnitzii; 9. Desulfovibrio 
spp.; 10. Akk. muciniphila; 11. Firmicutes; 12. Bacteroidetes; 13. Roseburia spp.; 14. Bacteroides 
spp.; 15. Alistipes spp.; 16. Actinobacteria; 17. Bac. fragilis group; 18. Clostridiaceae/Eubacterium. 
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Figure 3 Principal Component Analysis of LCMS data from the mucosal M-SHIME samples 
after colonization with microbiota derived from either healthy subjects (о) or UC patients in relapse 
(∆). Score (left) and loading (right) plots are shown. PC1 and PC2 explain 29.1% and18.6% of the 
variance, respectively. Numbers from 1 to 10 in the loading plot correspond to metabolite 
candidates enriched in the M-SHIME mucin-coveres microcosms.. Masses of the candidates are 
given in Table 4. 
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Figure 4 Principal Component Analysis of the LCMS data from the luminal M-SHIME samples 
after colonization with microbiota derived from healthy subjects (о) or UC patients in relapse (∆). 
Score (left) and loading (right) plots are shown. PC1 and PC2 explain 26.2% and 21.8% of the 
variance, respectively. Numbers from 11-17 in the loading plot correspond to metabolite 
candidates that are enriched in the luminal M-SHIME samples. Masses of the candidates are given 
in Table 5.  
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Supplementary figures 
 
 
 
 
Figure S1 PCA of LCMS data from mucosal samples of M-SHIME colonized with microbiota 
from healthy subjects (о) and UC patients in remission (x). Score (left) and loading (right) plots are 
shown. Presented PC1 (36.3%) vs. PC2 (16.4%). 
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Figure S2 PCA of LCMS data from luminal samples of M-SHIME colonized with microbiota from 
healthy subjects (о) and UC patients in remission (x). Score (left) and loading (right) plots are 
shown. Presented PC1 (30.3%) vs. PC2 (17.5%).  
 
 
 
 
Figure S3 PCA of LCMS data from mucosal samples of M-SHIME colonized with microbiota 
from UC patients in relapse (∆) and in remission (x). Score (left) and loading (right) plots are 
shown. Presented PC1 (33.7%) vs. PC2 (17.5%). Numbers in the loading plot, bucket mass from 
the PCA /retention time bucket, correspond to the metabolite candidates described in Table 4. 
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Figure S4 PCA of LCMS data from luminal samples of M-SHIME colonized with microbiota from 
UC patients in relapse (∆) and in remission (x). Score (left) and loading (right) plots are shown. 
Presented PC1 (26.9%) vs. PC2 (17.4%). Numbers in the loading plot, bucket mass from the PCA 
/retention time bucket, correspond to the metabolite candidates described in Table 5. 
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Discussion and final conclusions 
 
The human gastrointestinal tract is a very complex system of interactions between 
microflora, diet and the host. Biochemical messages can be sent by many different types 
of molecules, including metabolites [199]. Metabolic footprinting represents only a small 
fraction of the whole metabolome; however it provides a key understanding of cell and 
organism communication mechanisms, which play a crucial role in the symbiotic 
relationships between GIT microflora and the host. In an extracellular environment any 
changes in the abundance and level of extracellular metabolites will directly reflect any 
modifications of the environment caused by activities of microorganism present in the 
system [18]. Due to the chemical and physical differences between various metabolites in 
the metabolome and due to the data overload, metabolomic studies are mainly focused on 
the differences between samples. Additionally, metabolic footprinting in the sample 
preparation is straightforward, when combined with the in vitro fermentation studies.  
Therefore, in order to analyze the response of Lactobacillus acidophilus NCFM to a 
surrounding environment, starting pH of fermentations was set to 3, 5 and 7. As expected, 
NCFM did not grow in the low pH environment, but this has been used as a base to study 
the potential interactions of NCFM with the GIT surroundings at pH 5 and 7, as 
encountered throughout the human GIT. In vitro studies with NCFM showed that this strain 
in the presence of a simple carbohydrate source (glucose) increased the concentration of 
lactic acid, succinic acid, adenine and arginine in the medium after 24 h of fermentation, 
using adenosine and glucose as the primary source of energy. As an influence of pH on 
the enzymatic activities of NCFM was suggested, still pH 5 or 7 was not a strong indicator 
of the NCFM colonization and qualitative metabolite production. Lactic acid and succinic 
acid, produced by the probiotic strain could have a beneficial effect on the host, lowering 
the pH in the intestines and thereby protecting from pathogenic infections and cancer 
development [200-202]. However, the GIT is much more complex environment that is 
affected by nutrition available for the bacterial fermentation and mammalian metabolites 
interacting with the probiotic. Therefore, a simplified mammalian model, the germ-free 
mice studies, was introduced to analyze the NCFM influence on the host. Previous studies 
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using Lactobacillus paracasei NCC2461 [203] to colonize germ-free mice showed a great 
influence of this strain on the metabolic profiles of intestinal tissues, consistent with 
modulation of intestinal digestion, absorption of nutrients, energy metabolism, lipid 
synthesis and protective functions. Our initial analyses, comparing germ-free and 
monocolonized animals with NCFM, showed a distinctive differences in the metabolism 
throughout the mammalian GIT as well as global metabolism, represented by plasma and 
liver samples. The characteristics of NCFM influence on the host by metabolite 
identification and comparison to the previous in vitro fermentations still remain to be 
addressed. On the other hand, the mouse germ-free model in the evaluation of the 
probiotic effects will not present all of the NCFM interaction encountered in the mammalian 
GIT. Simplification by removal of other microbiota from the gut could obscure the real 
picture of NCFM influence on the host and that is why human baby flora mice [204] and 
human clinical trials in connection to the metabolomics should be considered in the future.          
Metabolic footprinting was also introduced to the in vitro analysis of the non-digestable 
arabino-oligosaccharides (AOS). The prebiotic characteristics of selected carbohydrates in 
comparison to the established FOS were evaluated. Prebiotics are defined as ”selectively 
fermented ingredients that allow specific changes, both in the composition and/or activity 
of the gastrointestinal microbiota that confers benefits upon host well-being and health” [7]. 
Changes in the composition of the fecal microflora in connection to the size (chain length) 
of AOS were analyzed by qPCR, and the metabolic activity studies were focused on the 
metabolite production. The metabolic response to high-mass AOS was found to be the 
most similar to FOS, correlating to the microbial changes in the fecal microflora. High-
mass AOS in comparison to the low-mass and base fraction caused the highest increase 
of metabolites putatively beneficial to the human GIT. However, an in vitro metabolic 
system altered by the presence of AOS, even with a full fecal microflora, might be 
developing differently than the one in the gut environment. As the bacterial composition 
differ greatly throughout the GIT [59], so can the metabolic response. Therefore, in order 
to evaluate the full response, just like in the probiotic studies, human clinical trials should 
be taken into consideration.     
Probiotic and prebiotic influence on the host looks for the beneficial aspect of the bacterial 
flora. GIT is not only inhabited by beneficial microbiota, but also potential pathogens. A 
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balanced microflora requires that the bacterial composition work in a co-metabolic 
symbiotic relationship with the host, supporting the complex system. An unbalanced 
composition might potentially be the beginning of many diseases, such as inflammatory 
bowel diseases, in particular Ulcerative Colitis (UC) [205,206]. Several studies have shown 
that patients with UC have an altered bacterial microbiota [207-209]. Bacterial alterations 
might lead to the metabolic response of the microflora. Metabolomic footprinting has 
shown the significant differences in the metabolism between microflora from UC patients in 
relapse and remission or healthy individuals. In the UC studies Simulator of the Human 
Intestinal Microbial Ecosystem with incorporated mucin-covered microcosms (M-SHIME) 
was applied [210]. In search for the microbial metabolites exclusively, the dynamic gut 
model seems to be the best choice, possibly significantly lowering the impact of the 
individual diet as well as human-origin metabolites, still present in the fecal matter.    
Throughout all of the studies in relation to the bacterial impact on the gut metabolome 
LCMS and DIMS in connection to the PCA was used. PCA in metabolomics is used 
extensively as an unsupervised method in search for the differences in metabolome 
between given settings [6,17]. However, a choice of chemical analysis in parallel with a 
sample preparation is always a matter of discussion. A wide range of analytical tools is 
used in metabolomics [18]. DIMS allows high-throughput analyses of biological samples. 
The major problem with DIMS technology is the matrix effect and even with the usage of 
TOF spectrometer, not good enough separation of metabolites. The mentioned effect can 
also compromise the sensitivity and accuracy of mass analysis [29]. Ion suppression 
caused by coeluting compounds and isobaric interferences are also a major disadvantage 
of DIMS. Liquid chromatography gives a good separation of metabolites. With LCMS a 
very wide range of metabolites can be covered by this method through the ionization in 
positive and negative mode with a very good sensitivity. LCMS sample preparation is very 
easy and straightforward. LCMS makes possible analysis of thermo-labile metabolites. A 
few drawbacks of this system are possible matrix effects, sometimes requiring the 
desalting of samples, limited structural information and identification, overcome by use of 
MS-MS techniques [34,35]. The choice of DIMS and LCMS in the study of complex 
metabolome was based on the positive aspects of both methods, our good results during 
the preliminary studies and instrument availability, 
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In conclusion, the experimental studies included in this thesis add to our understanding of 
bacterial impact on the gut metabolome. The new knowledge gained includes 
Lactobacillus acidophilus NCFM metabolite production and a possible alteration of 
mammalian host metabolome, AOS ability to change the overall composition of the fecal 
microbiota and their metabolic interactions with possible beneficial aspect of the high-mass 
carbohydrates. Additionally, a metabolomic-angled look on the UC allowed to constitute an 
important contribution to the understanding of the complex etiology of UC. 
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